U.S. patent application number 14/165705 was filed with the patent office on 2014-06-12 for n-terminus conformationally constrained glp-1 receptor agonist compounds.
This patent application is currently assigned to ASTRAZENECA PHARMACEUTICALS, LP. The applicant listed for this patent is AMYLIN PHARMACEUTICALS, LLC, ASTRAZENECA PHARMACEUTICALS, LP. Invention is credited to Josue ALFARO-LOPEZ, Soumitra S. GHOSH, Abhinandini SHARMA.
Application Number | 20140162943 14/165705 |
Document ID | / |
Family ID | 42983065 |
Filed Date | 2014-06-12 |
United States Patent
Application |
20140162943 |
Kind Code |
A1 |
ALFARO-LOPEZ; Josue ; et
al. |
June 12, 2014 |
N-TERMINUS CONFORMATIONALLY CONSTRAINED GLP-1 RECEPTOR AGONIST
COMPOUNDS
Abstract
The disclosure provides N-terminus conformationally constrained
compounds, which may comprise peptide mimetics and/or amino acid
substitutions, which may be used in peptides, such as GLP-1
receptor agonist compounds, to induce .beta.-turn secondary
structure at the N-terminus. The N-terminus conformationally
constrained compounds may be used for research purposes; to produce
GLP-1 receptor agonist compounds having improved GLP-1 receptor
binding activity, enzymatic stability, or in vivo glucose lowering
activity; and to develop GLP-1 receptor agonist compounds which
have fewer amino acid residues. The disclosure also provides GLP-1
receptor agonist compounds, such as exendins, exendin analogs,
GLP-1(7-37), GLP-1(7-37) analogs, comprising the N-terminus
conformationally constrained compounds. The compounds are useful
for treating various diseases, such as diabetes and obesity. The
disclosure also provides methods for chemically synthesizing the
N-terminus conformationally constrained compounds.
Inventors: |
ALFARO-LOPEZ; Josue; (San
Diego, CA) ; SHARMA; Abhinandini; (SAN DIEGO, CA)
; GHOSH; Soumitra S.; (SAN DIEGO, CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
ASTRAZENECA PHARMACEUTICALS, LP
AMYLIN PHARMACEUTICALS, LLC |
WILMINGTON
SAN DIEGO |
DE
CA |
US
US |
|
|
Assignee: |
ASTRAZENECA PHARMACEUTICALS,
LP
WILMINGTON
DE
AMYLIN PHARMACEUTICALS, LLC
SAN DIEGO
CA
|
Family ID: |
42983065 |
Appl. No.: |
14/165705 |
Filed: |
January 28, 2014 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13260702 |
Oct 27, 2011 |
8642544 |
|
|
PCT/US10/28883 |
Mar 26, 2010 |
|
|
|
14165705 |
|
|
|
|
61165604 |
Apr 1, 2009 |
|
|
|
Current U.S.
Class: |
514/4.9 ;
514/11.7; 514/4.8; 514/6.8; 514/7.2; 530/308 |
Current CPC
Class: |
C07K 14/46 20130101;
C07K 14/605 20130101; A61P 3/04 20180101; A61K 38/00 20130101; A61P
3/10 20180101 |
Class at
Publication: |
514/4.9 ;
530/308; 514/7.2; 514/6.8; 514/4.8; 514/11.7 |
International
Class: |
C07K 14/605 20060101
C07K014/605 |
Claims
1-130. (canceled)
131. A polypeptide comprising the amino acid sequence as set forth
in Formula (C): TABLE-US-00010 (SEQ ID NO: 2)
Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4TFTSDLSKQXaa.sub.14EEEAVRLFIEXaa.sub.2-
5LK-R.sub.10-Z;
wherein: Xaa.sub.1 is His; or a compound of Formula (1); Xaa.sub.2
is Gly, dAla, Aib, Ala, Val, NMeAla, a compound of Formula (3), or
a compound of Formula (4); and Xaa.sub.2 is absent when Xaa.sub.3
is: ##STR00021## Xaa.sub.3 is Pro; a compound of Formula (2); a
compound of Formula (3); a Compound of Formula (4); ##STR00022##
Xaa.sub.4 is Gly, dAla, or Aib; Xaa.sub.14 is Leu or Met;
Xaa.sub.25 is Phe or Trp; R.sub.10 is QGGPSKEIIS (SEQ ID NO:22);
NG; NGG; NGGP (SEQ ID NO:24); NGGPS (SEQ ID NO:25); NGGPSS (SEQ ID
NO:26); NGGPSSG (SEQ ID NO:27); NGGPSSGA (SEQ ID NO:28); NGGPSSGAP
(SEQ ID NO:29); NGGPSSGAPP (SEQ ID NO:30); NGGPSSGAPPP (SEQ ID
NO:31); QGGPSSGAPPPS (SEQ ID NO:32); NGGPSSGAPPS (SEQ ID NO:33);
NGGPSSGAPPSK (SEQ ID NO:34); NGGPSSGAPPS(K).sub.2-5 (SEQ ID NO:35);
NGGPSSGAPPPSK (SEQ ID NO:36); or NK; and Z is OH or NH.sub.2;
wherein the compound of Formula (1) is: ##STR00023## wherein
R.sub.20 and R.sub.21 are each independently a single bond or a
carbon atom; R.sub.23, R.sub.24, R.sub.25 and R.sub.26 are each
independently absent, hydrogen, hydroxyl, C.sub.1-6 alkyl,
carboxyl, amino, or C.sub.1-6 alkoxy; - - - - - - is a single bond
or a double bond; and R.sub.21 is a chiral or achiral carbon atom;
wherein the compound of Formula (2) is: ##STR00024## wherein
Y.sub.1 and Z.sub.1 are each independently a single bond, a carbon,
or a sulfur; and W.sub.1, W.sub.2 and W.sub.3 are each
independently selected from hydrogen, C.sub.1-6 alkyl, C.sub.1-6
alkoxy, hydroxyl, and amino; and when one Y.sub.1 or Z.sub.1 is
sulfur, the sulfur may be bonded to two oxygen atoms to form a
sulfonyl group; and - - - - - - is or ; wherein the compound of
Formula (3) is: ##STR00025## wherein Y.sub.1 and Z.sub.1 are each
independently a single bond, a carbon, or a sulfur; and W.sub.1,
W.sub.2 and W.sub.3 are each independently selected from hydrogen,
C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxyl, and amino; and when
one Y.sub.1 or Z.sub.1 is sulfur, the sulfur may be bonded to two
oxygen atoms to form a sulfonyl group; and - - - - - - is or ; and
wherein the compound of Formula (4) is: ##STR00026## wherein
R.sub.30, R.sub.31, and R.sub.32 are each independently hydrogen or
a C.sub.1-6 alkyl; or R.sub.30 and R.sub.31, together with the
nitrogen.sup.1 and the carbon.sup.2, form a 5-membered or
6-membered heterocyclic ring; or R.sub.31 and R.sub.32, together
with the carbon.sup.2, form a 3-, 4-, or 5-membered carbocyclic
ring.
132. The polypeptide of claim 131, wherein Xaa.sub.3 is Pro.
133. The polypeptide of claim 132, wherein the polypeptide
comprises the sequence set forth as: Pro.sup.3-exendin-4 (SEQ ID
NO:40); Pro.sup.3,Leu.sup.14-exendin-4 (SEQ ID NO:41);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4 (SEQ ID NO:42);
Pro.sup.3-exendin-4(1-28) (SEQ ID NO:43);
Pro.sup.3,Leu.sup.14-exendin-4(1-28) (SEQ ID NO:44);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-28) (SEQ ID NO:45);
Pro.sup.3-exendin-4(1-29) (SEQ ID NO:51);
Pro.sup.3,Leu.sup.14-exendin-4(1-29) (SEQ ID NO:75);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-29) (SEQ ID NO:52);
Pro.sup.3-exendin-4(1-30) (SEQ ID NO:53);
Pro.sup.3,Leu.sup.14-exendin-4(1-30) (SEQ ID NO:76);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-30) (SEQ ID NO:54);
Pro.sup.3-exendin-4(1-31) (SEQ ID NO:55);
Pro.sup.3,Leu.sup.14-exendin-4(1-31) (SEQ ID NO:77);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-31) (SEQ ID NO:56);
Pro.sup.3-exendin-4(1-32) (SEQ ID NO:57);
Pro.sup.3,Leu.sup.14-exendin-4(1-32) (SEQ ID NO:78);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-32) (SEQ ID NO:58);
Pro.sup.3-exendin-4(1-33) (SEQ ID NO:59);
Pro.sup.3,Leu.sup.14-exendin-4(1-33) (SEQ ID NO:79);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-33) (SEQ ID NO:60);
Pro.sup.3-exendin-4(1-34) (SEQ ID NO:61);
Pro.sup.3,Leu.sup.14-exendin-4(1-34) (SEQ ID NO:80);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-34) (SEQ ID NO:62);
Pro.sup.3-exendin-4(1-35) (SEQ ID NO:63);
Pro.sup.3,Leu.sup.14-exendin-4(1-35) (SEQ ID NO:81);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-35) (SEQ ID NO:64);
Pro.sup.3-exendin-4(1-36) (SEQ ID NO:46);
Pro.sup.3,Leu.sup.14-exendin-4(1-36) (SEQ ID NO:47);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-36) (SEQ ID NO:48);
Pro.sup.3-exendin-4(1-37) (SEQ ID NO:65);
Pro.sup.3,Leu.sup.14-exendin-4(1-37) (SEQ ID NO:82);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-37) (SEQ ID NO:66);
Pro.sup.3-exendin-4(1-38) (SEQ ID NO:67);
Pro.sup.3,Leu.sup.14-exendin-4(1-38) (SEQ ID NO:83);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-38) (SEQ ID NO:68);
Pro.sup.3-exendin-3 (SEQ ID NO:50); or
HGPGTFTSDLSKQLEEEAVRLFIEWLKQGGPSKEIIS (SEQ ID NO:49).
134. A method for treating diabetes, treating insulin resistance,
treating postprandial hyperglycemia, lowering blood glucose levels,
lowering HbA1c levels, stimulating insulin release, reducing
gastric motility, delaying gastric emptying, reducing food intake,
reducing appetite, reducing weight, treating overweight, or
treating obesity in a patient in need thereof, the method
comprising: administering to the patient a therapeutically
effective amount of the peptide of claim 131 to treat diabetes,
treat insulin resistance, treat postprandial hyperglycemia, lower
blood glucose levels, lower HbA1c levels, stimulate insulin
release, reduce gastric motility, delay gastric emptying, reduce
food intake, reduce appetite, reduce weight, treat overweight, or
treat obesity in the patient.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a divisional of U.S. application Ser.
No. 13/260,702, filed on Sep. 27, 2011, which is a U.S. national
stage of International Application No. PCT/US2010/28883, filed Mar.
26, 2010, which claims priority to U.S. Application No. 61/165,604
filed Apr. 1, 2009.
FIELD
[0002] Provided herein are N-terminus conformationally constrained
GLP-1 receptor agonist compounds and therapeutic methods for their
use.
BACKGROUND
[0003] Peptides and proteins play critical roles in the regulation
of biological processes. Peptides, for example, play a regulatory
role as hormones and inhibitors, and are also involved in
immunological recognition. The significant biological role of
peptides makes it important to understand their interactions with
the receptors to which they bind.
[0004] The determination of the receptor-bound conformation of a
peptide is invaluable for the rational design of peptide analogs.
Marshall et al, Ann. Rep. Med. Chem., 13:227-238 (1978) disclose
that peptides are characteristically highly flexible molecules, the
structures of which are strongly influenced by the environment in
which they reside. Thus, peptides are not generally useful for
determining their receptor-bound conformation.
[0005] As no approach is available to predict which new
ligand-receptor interactions will lead to antagonists and which
will lead to agonists of greater or less potency, it is necessary
to perform classical structure-function studies in a systematic way
to provide information about the specific amino acid residues and
functional groups in a peptide that are important to biological
activity. Studies of this nature can utilize conformationally
constrained peptide mimetics. For example, Hruby, Trends Pharmacol.
Sci., 8:336-339 (1987) suggests that conformational constraints can
provide information about the different requirements that a
receptor has for a ligand to be an agonist or antagonist.
[0006] Generally, peptide mimetics can be defined as structures
which serve as appropriate substitutes for peptides in interactions
with receptors and enzymes. The development of rational approaches
for discovering peptide mimetics is a major goal of medicinal
chemistry. Such development has been attempted both by empirical
screening approaches and by specific synthetic design. Specific
design of peptide mimetics has utilized both peptide backbone
modifications and chemical mimics of peptide secondary structures.
The beta-turn has been implicated as an important site for
molecular recognition in many biologically active peptides.
Consequently, peptides containing conformationally constrained
mimetics of beta-turns are particularly desirable.
[0007] There is a need in the art for new GLP-1 receptor agonist
compounds that have good stability, resistance to degradation, and
good glucagon-like peptide-1 (GLP-1) receptor binding activity and
in vivo glucose lowering activity. To solve these needs, the
disclosure herein provides, among other things, novel N-terminus
conformationally constrained compounds, novel N-terminus
conformationally constrained GLP-1 receptor agonist compounds
containing modifications, such as peptide mimetics and/or amino
acid substitutions, that provide a conformationally constrained
N-terminus that results in improved GLP-1 receptor binding and in
vivo blood glucose lowering activity.
SUMMARY
[0008] It was previously believed that the N-terminus of exendin-4
and exendin analogs was a random coil. It has now been unexpectedly
discovered that the N-terminus shows a high beta-turn
characteristic in a specific site, and therefore mimics the
receptor bound conformation of this region of the peptides. The
disclosure herein is based on this discovery.
[0009] Provided herein are N-terminus conformationally constrained
compounds having the formula: Xaa.sub.1Xaa.sub.2Xaa.sub.3-Z and
Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4-Z, where the substituents are
defined herein. These N-terminus conformationally constrained
compounds may induce a .beta.-turn conformational constraint at the
N-terminus when they are used in GLP-1 receptor agonist compounds.
The N-terminus conformationally constrained compounds may be used
for therapeutic purposes (e.g., treat diabetes); for research
purposes; and to produce GLP-1 receptor agonist compounds having
improved GLP-1 receptor binding activity, enzymatic stability, and
improved in vivo glucose lowering activity. The disclosure provides
pharmaceutical compositions comprising therapeutically effective
amounts of the N-terminus conformationally constrained compounds.
The disclosure also provides methods for synthesizing the
N-terminus conformationally constrained compounds.
[0010] Provided herein are GLP-1 receptor agonist compounds, such
as exendins, exendin analogs, GLP-1(7-37) (SEQ ID NO: 84), and
GLP-1(7-37) analogs, comprising an N-terminus conformationally
constrained compound having the formula
Xaa.sub.1Xaa.sub.2Xaa.sub.3- or
Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4-, where the substituents are
defined herein. In one embodiment, the GLP-1 receptor agonist
compounds comprise Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4, where the
substituents are defined herein, at positions 1-4 at the
N-terminus. In one embodiment, the GLP-1 receptor agonist compounds
comprise Xaa.sub.1Xaa.sub.2Xaa.sub.3, where the substituents are
defined herein, at positions 1-3 at the N-terminus. The disclosure
provides pharmaceutical compositions comprising therapeutically
effective amounts of these N-terminus conformationally-constrained
GLP-1 receptor agonist compounds.
[0011] Provided herein are exendins and exendin analogs having the
formula:
TABLE-US-00001 (SEQ ID NO: 1)
Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4TFTSDLSKQXaa.sub.14EEEAVRLFIEXaa.sub.2-
5LKN-Z; (SEQ ID NO: 2)
Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4TFTSDLSKQXaa.sub.14EEEAVRLFIEXaa.sub.2-
5LK-R.sub.10-Z; (SEQ ID NO: 3)
Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4TFTSDLSKQXaa.sub.14EEEAVRLFIEXaa.sub.2-
5 LKNGGPSSGAPPPS-Z;
where Xaa.sub.14, Xaa.sub.25, R.sub.10, and Z are defined herein;
and at least one of Xaa.sub.1, Xaa.sub.2, Xaa.sub.3, and Xaa.sub.4
are modifications, such as peptide mimetics and/or amino acid
substitutions, that induce a conformational constraint at the
N-terminus. The disclosure provides pharmaceutical compositions
comprising therapeutically effective amounts of these exendin
analogs.
[0012] Provided herein are GLP-1(7-37) (SEQ ID NO: 84) and
GLP-1(7-37) analogs having the formula:
TABLE-US-00002 (SEQ ID NO: 4)
Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4TFTSDVSSYXaa.sub.14EGQAAKEFIAXaa.sub.-
25 LVXaa.sub.28GRXaa.sub.31-Z;
where Xaa.sub.14, Xaa.sub.25, Xaa.sub.28, Xaa.sub.31, and Z are as
defined herein; and at least one of Xaa.sub.1, Xaa.sub.2,
Xaa.sub.3, and Xaa.sub.4 are modifications, such as peptide
mimetics and/or amino acid substitutions, that induce a
conformational constraint at the N-terminus. The disclosure
provides pharmaceutical compositions comprising therapeutically
effective amounts of these GLP-1(7-37) analogs.
[0013] Provided herein are GLP-1 receptor agonist compounds, such
as exendins, exendin analogs, GLP-1(7-37) (SEQ ID NO: 84), and
GLP-1(7-37) analogs wherein position 1 comprises an imidazole ring
(e.g., His) and position 3 is proline; where the GLP-1 receptor
agonist compounds bind in a RIN cell membrane receptor binding
assay with an affinity of less than 1 nM (or less than 0.1 nM).
[0014] The disclosure provides methods for treating diabetes;
treating insulin resistance; treating postprandial hyperglycemia;
lowering blood glucose levels; lowering HbA1c levels; stimulating
insulin release; reducing gastric motility; delaying gastric
emptying; reducing food intake; reducing appetite; reducing weight;
treating overweight; and treating obesity in patients in need by
administering therapeutically effective amounts of the N-terminus
conformationally constrained compounds and/or the N-terminus
conformationally constrained GLP-1 receptor agonist compounds
described herein.
BRIEF DESCRIPTION OF THE FIGURES
[0015] FIG. 1: FIG. 1A is exendin-4 amide (SEQ ID NO: 86); FIG. 1B
is dAla.sup.2,Pro.sup.3-exendin-4 amide, and FIG. 1C is
dAla.sup.2,Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4 (1-28) amide.
FIG. 1D is a graph showing the change in blood glucose in mice
administered the compounds shown in FIGS. 1A-C based on the in vivo
blood glucose assay described in Example 17. The compounds were
injected IP at t=0 immediately following a baseline sample in
2-hour fasted NIH/Swiss mice. Blood glucose samples were taken at
t=30, 60, 120, 180, and 240 minutes with a ONETOUCH.RTM. ULTRA.RTM.
(LifeScan, Inc., Milpitas, Calif.).
[0016] FIG. 2: FIG. 2A is an exendin analog (SEQ ID NO: 87),
described, e.g., in WO 2007/139941. FIGS. 2B-J show the exendin
analog of FIG. 2A having a modification at Glu.sup.3. R.sub.1 is
GTFTSDLSKQLEEEAVRLFIEWLKQGGPSKEIIS-NH.sub.2 (SEQ ID NO: 5). FIG. 2K
shows the exendin analog (SEQ ID NO: 5) of FIG. 2A having
modifications at Gly.sup.2Glu.sup.3. FIGS. 2L-2U show N-terminus
conformationally constrained compounds. FIGS. 2B-J provide examples
of exendin analogs containing the N-terminus conformationally
constrained compounds shown in FIGS. 2L-2U.
[0017] FIGS. 3A-G are dAla.sup.2,Pro.sup.3-exendin-4 (FIG. 3A),
Ala.sup.2,Pro.sup.3-exendin-4 (SEQ ID NO: 88) (FIG. 3B),
Pro.sup.3,Ala.sup.4-exendin-4 (SEQ ID NO: 89) (FIG. 3C),
Ala.sup.2,Pro.sup.3,Ala.sup.4-exendin-4 (SEQ ID NO: 90) (FIG. 3D),
Pro.sup.3,dAla.sup.4-exendin-4 (FIG. 3E),
Val.sup.2,Pro.sup.3-exendin-4 (SEQ ID NO: 91) (FIG. 3F), and
NMeAla.sup.2,Pro.sup.3-exendin-4 (SEQ ID NO: 92) (FIG. 3G). The
compound in FIGS. 1B and 3A are the same.
[0018] FIG. 4 is a graph showing the change in blood glucose in
mice administered the compounds shown in FIGS. 3G, 2I, and 2B based
on the in vivo blood glucose assay described in Example 17. The
compounds were injected IP at t=0 immediately following a baseline
sample in 2-hour fasted NIH/Swiss mice. Blood glucose samples were
taken at t=30, 60, 120, 180, and 240 minutes with a ONETOUCH.RTM.
ULTRA.RTM. (LifeScan, Inc., Milpitas, Calif.).
[0019] FIG. 5: FIG. 5A is Leu.sup.14,Phe.sup.25-exendin-4(1-28)
(SEQ ID NO: 93), described in WO 2007/139941.
Leu.sup.14,Phe.sup.25-exendin-4(1-28) (SEQ ID NO: 93) refers to
amino acid residues 1-28 in exendin-4 (i.e., exendin-4(1-28) (SEQ
ID NO: 99), where the amino acid residue at position 14 in
exendin-4 is replaced with Leu (i.e., Leu.sup.14), and the amino
acid residue at position 25 is replaced with Phe (i.e.,
Phe.sup.25). FIGS. 5B-G show the exendin analog of FIG. 5A having a
modification at Glu.sup.3 or Gly.sup.2Glu.sup.3 at the N-terminus.
R.sub.4 is GTFTSDLSKQLEEEAVRLFIEFLKN-NH.sub.2 (SEQ ID NO: 6).
[0020] FIGS. 6A-E show the exendin analog of FIG. 5A having a
modification at Gly.sup.2Glu.sup.3 or Gly.sup.2Glu.sup.3Gly.sup.4
at the N-terminus. The C-terminal amino acid in each compound shown
in FIGS. 6A-E is amidated. FIGS. 6A through 6D disclose SEQ ID NOS
94 and 94-96, respectively.
[0021] FIG. 7 is a graph showing the change in blood glucose in
mice administered the compounds shown in FIGS. 6A, 8B, 6E, 1C, 5B,
and 5A based on the in vivo blood glucose assay described in
Example 17. The compounds were injected IP at t=0 immediately
following a baseline sample in 2-hour fasted NIH/Swiss mice. Blood
glucose samples were taken at t=30, 60, 120, 180, and 240 minutes
with a ONETOUCH.RTM. ULTRA.RTM. (LifeScan, Inc., Milpitas,
Calif.).
[0022] FIG. 8: FIGS. 8A-D show the exendin analog in FIG. 5A having
modifications at Gly.sup.2Glu.sup.3Gly.sup.4 at the N-terminus,
where the C-terminal amino acid is amidated. FIGS. 8E-H show the
exendin analog in FIG. 2A having modifications at
Gly.sup.2Glu.sup.3Gly.sup.4 at the N-terminus. FIGS. 8A and 8E
disclose SEQ ID NOS 97-98, respectively.
[0023] FIG. 9: FIGS. 9A-H show the exendin analog in FIG. 5A having
a modification at Gly.sup.2Glu.sup.3 or Gly.sup.2Glu.sup.3Gly.sup.4
at the N-terminus. Each compound in FIGS. 9A-H is amidated at the
C-terminal amino acid. FIGS. 9A through 9H disclose SEQ ID NOS 6,
6, 6, 6, 100, 6, 6 and 6, respectively. FIG. 9I is a graph showing
the change in blood glucose in mice administered the compounds
shown in FIGS. 9B, 9C, 9D, 9F, 5A, and 1C based on the in vivo
blood glucose assay described in Example 17. The compounds were
injected IP at t=0 immediately following a baseline sample in
2-hour fasted NIH/Swiss mice. Blood glucose samples were taken at
t=30, 60, 120, 180, and 240 minutes with a ONETOUCH.RTM. ULTRA.RTM.
(LifeScan, Inc., Milpitas, Calif.).
[0024] FIGS. 10A-I show the exendin analog in FIG. 5A having a
modification at His.sup.1 at the N-terminus. R.sub.4 is
Xaa.sub.2Xaa.sub.3GTFTSDLSKQLEEEAVRLFIEFLKN-NH.sub.2 (SEQ ID NO:
7), where Xaa.sub.2 is Gly, dAla, or Aib; and Xaa.sub.3 is Glu or
Pro. Alternatively, R.sub.4 is Xaa.sub.2Xaa.sub.3GTFTSDLSKQLEEEA
VRLFIEWLKNGGPSSGAPPPS-NH.sub.2 (SEQ ID NO: 8), where Xaa.sub.2 is
Gly, dAla, or Aib; and Xaa.sub.3 is Glu or Pro; provided that
Xaa.sub.3 is not Glu when Xaa.sub.2 is Gly, or Xaa.sub.2 is not Gly
when Xaa.sub.3 is Glu. Alternatively, R.sub.4 is
Xaa.sub.2Xaa.sub.3GTFTSDLSKQLEEEAVRLFIEWLKQGGPSKEIIS-OH (SEQ ID NO:
9), where Xaa.sub.2 is Gly, dAla, or Aib; and Xaa.sub.3 is Glu or
Pro.
[0025] FIGS. 11A-B show exendin-4 of FIG. 1A having a modification
at His.sup.1 at the N-terminus. R.sub.2 is
GEGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPPS-NH.sub.2 (SEQ ID NO:
10).
[0026] FIG. 12 shows the compound of FIG. 10E with an amino acid
substitution of Trp.sup.25. The compound in FIG. 12 is amidated at
the C-terminal amino acid residue (SEQ ID NO: 101).
[0027] FIG. 13 shows an exendin analog having a modification at
His.sup.1Gly.sup.2Glu.sup.3. The compound in FIG. 13 is amidated at
the C-terminal amino acid residue (SEQ ID NO: 102).
[0028] FIG. 14: FIG. 14A is a generic structure (where Xaa.sub.2
is, e.g., Gly, dAla, or Aib; and the other substituents are defined
herein) of an exendin analog of FIG. 1A, 2A, or 5A having
modifications at His.sup.1Gly.sup.2Glu.sup.3 at the N-terminus,
where R is a peptide, such as any one of the following:
GTFTSDLSKQLEEEAVRLFIEFLKN-NH.sub.2 (SEQ ID NO: 6);
GTFTSDLSKQLEEEAV-RLFIEWLKQGGPSKEIIS-OH (SEQ ID NO: 5); or
GTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPPS-NH.sub.2 (SEQ ID NO: 11). Aib
is .alpha.-methylalanine FIGS. 14B-C are examples of compounds from
the structure in FIG. 14A that have modifications at His.sup.1 and
Glu.sup.3. The compounds in FIGS. 14B-C are amidated at the
C-terminal amino acid residue. FIGS. 14B through 14C disclose SEQ
ID NOS 6 and 6, respectively. FIG. 14D provides the generic
structure (where Xaa.sub.2 is Gly, dAla, or Aib; and the other
substituents are defined herein) of an N-terminus conformationally
constrained compound. FIGS. 14E-R are exendin analogs comprising an
N-terminus conformationally constrained compound. FIG. 14Q
discloses SEQ ID NO: 38. R.sub.1 is GTFTSDLSKQLEEEAVRLF
IEWLKQGGPSKEIIS-OH (SEQ ID NO: 5). R.sub.4 is
GTFTSDLSKQLEEEAVRLFIEFLKN-NH.sub.2 (SEQ ID NO: 6). R.sub.5 is
PGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPPS-NH.sub.2 (SEQ ID NO: 12).
[0029] FIGS. 15A-D are exendin analogs that comprise isomers of
nipecotic acid as the N-terminus conformationally constrained
compound. R.sub.1 is FTSDLSKQLEEEAVRLFI EWLKQGGPSKEIIS-NH.sub.2
(SEQ ID NO: 13).
[0030] FIG. 16: FIGS. 16A-H are exendin analogs containing a
modification at the N-terminus. R.sub.1 is
FTSDLSKQLEEEAVRLFIEWLKQGGPSKEIIS-OH (SEQ ID NO: 13). R.sub.2 is
FTSDLSKQLE EEAVRLFIEWLKNGGPSSGAPPPS-NH.sub.2 (SEQ ID NO: 14).
R.sub.3 is FTSDVSSYLEGQAAKEFIAWLVKGRG-NH.sub.2 (SEQ ID NO: 15).
FIGS. 16I-L are exendin analogs containing a modification at the
N-terminus. The modification is designed to mimic amino acid
residues His.sup.1Gly.sup.2Glu.sup.3. R.sub.4 is GTFTSDLSKQLEE
EAVRLFIEFLKN-NH.sub.2 (SEQ ID NO: 6).
[0031] FIG. 17: FIGS. 17A-F are exendin analogs containing a
thiazolidine-proline peptide mimetics at Gly.sup.2Glu.sup.3.
R.sub.4 is GTFTSDLSKQLEEEAVRLFIEFLKN-NH.sub.2 (SEQ ID NO: 6). FIGS.
17G-N are exendin analogs having a modification at His.sup.1 and
containing a thiazolidine peptide mimetic at Gly.sup.2Glu.sup.3.
R.sub.1, R.sub.2, and R.sub.3 are each independently hydrogen,
methyl, or ethyl. In this embodiment, Xaa.sub.3 is Glu, Asp, Pro,
or Gly. R.sub.4 is GTFTSDLSKQLEEEAVRLFIEFLKN-NH.sub.2 (SEQ ID NO:
6).
[0032] FIG. 18: FIG. 18A is a process for preparing
(5,5)-Glu-Gly-OH, a dipeptide mimetic that can be used to induce a
.beta.-turn conformational constraint, for example, at the
N-terminus in a GLP-1 receptor agonist compound. FIG. 18B is a
generic structure of the compound that can be produced by the
process shown in FIG. 18A. The skilled artisan can choose compounds
with different stereochemistries during the reaction process to
provide for various stereochemistries in the final product. *
represents a chiral carbon atom.
[0033] FIG. 19: FIG. 19A is a process for preparing .gamma.-lactam
Glu-Gly-OH, a dipeptide mimetic that can be used to induce a
.beta.-turn conformational constraint, for example, at the
N-terminus in a GLP-1 receptor agonist compound. FIG. 19B is a
generic structure of the compound that can be produced by the
process shown in FIG. 19A. The skilled artisan can choose compounds
with different stereochemistries during the reaction process to
provide for various stereochemistries in the final product. *
represents a chiral carbon atom.
[0034] FIG. 20: FIG. 20A is a process for preparing
(6,5)-Asp-Gly-OH, a dipeptide mimetic that can be used to induce a
.beta.-turn conformational constraint, for example, at the
N-terminus in a GLP-1 receptor agonist compound. FIG. 20B is a
generic structure of the compound that can be produced by the
process shown in FIG. 20A. The skilled artisan can choose compounds
with different stereochemistries during the reaction process to
provide for various stereochemistries in the final product. *
represents a chiral carbon atom.
[0035] FIG. 21: FIG. 21A is a process for preparing .delta.-lactam
Asp-Gly-OH and Asp-Ala-OH, both of which are dipeptide mimetics
that can be used to induce a .beta.-turn conformational constraint,
for example, at the N-terminus in a GLP-1 receptor agonist
compound. FIG. 21B is a generic structure of the compound that can
be produced by the process shown in FIG. 21A. The skilled artisan
can choose compounds with different stereochemistries during the
reaction process to provide for various stereochemistries in the
final product. * represents a chiral carbon atom.
[0036] FIG. 22 is a process for preparing a peptide mimetic which
can be used to induce a .beta.-turn conformational constraint, for
example, at the N-terminus in a GLP-1 receptor agonist compound.
FIG. 22 discloses SEQ ID NOS 103-104, respectively, in order of
appearance.
DETAILED DESCRIPTION
[0037] "GLP-1 receptor agonist compounds" refer to compounds that
elicit a biological activity of an exendin reference peptide (e.g.,
exendin-4) or a GLP-1(7-37) (SEQ ID NO: 84) reference peptide when
evaluated by art-known measures such as receptor binding studies or
in vivo blood glucose assays as described, e.g., Examples 16 and
17, and by Hargrove et al, Regulatory Peptides, 141:113-119 (2007),
the disclosure of which is incorporated by reference herein. GLP-1
receptor agonist compounds include, for example, native exendins,
exendin analogs, native GLP-1, GLP-1 analogs, GLP-1(7-37) (SEQ ID
NO: 84), and GLP-1(7-37) analogs.
[0038] The term "exendin" includes naturally occurring (or
synthetic versions of naturally occurring) exendin peptides that
are found in the salivary secretions of the Gila monster. Exendin-3
(HSDGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH.sub.2) (SEQ ID NO: 16)
is present in the salivary secretions of Heloderma horridum and
exendin-4 (FIG. 1A) is present in the salivary secretions of
Heloderma suspectum. Exendins include the amidated forms, the acid
form, the pharmaceutically acceptable salt form, and any other
physiologically active form of the molecule. In one embodiment, the
term exendin can be used interchangeably with the term "exendin
agonist."
[0039] "Exendin analog" refers to peptides, peptides containing
peptide mimetics, amino acid substitutions, and/or other
modifications, peptides containing the N-terminus conformationally
constrained compounds described herein, and/or other chemical
moieties, or other compounds which elicit a biological activity
similar to that of an exendin reference peptide (e.g., exendin-4),
when evaluated by art-known measures such as receptor binding
assays or in vivo blood glucose assays as described, e.g., Examples
16 and 17, and by Hargrove et al, Regulatory Peptides, 141:113-119
(2007), the disclosure of which is incorporated by reference
herein. Preferably, the exendin analogs will bind in such receptor
binding assays with an affinity of less than 1 .mu.M; an affinity
of less than 5 nM; an affinity of less than 1 nM, or an affinity of
less than 0.1 nM. In one embodiment, the term "exendin analog"
refers to a peptide that has an amino acid sequence with 1, 2, 3,
4, 5, 6, 7, or 8 amino acid substitutions, insertions, deletions,
or a combination of two or more thereof, when compared to the amino
acid sequence of exendin-4 shown in FIG. 1A. In other embodiment,
the term "exendin analog" refers to a peptide that has at least
85%, at least 88%, at least 90%, at least 93%, at least 95%, or at
least 98% sequence identity to the amino acid sequence of exendin-4
shown in FIG. 1A. Exendin analogs include the amidated forms, the
acid form, the pharmaceutically acceptable salt form, and any other
physiologically active form of the molecule. In one embodiment, the
term exendin analog can be used interchangeably with the term
"exendin agonist analog."
[0040] "GLP-1(7-37) analogs" refers to peptides, peptides
containing peptide mimetics and/or other modifications, peptides
containing the N-terminus conformationally constrained compounds
described herein, and/or other chemical moieties, or other
compounds which elicit a biological activity similar to that of
GLP-1(7-37) (SEQ ID NO: 84), when evaluated by art-known measures
such as receptor binding assays or in vivo blood glucose assays as
described, e.g., Examples 16 and 17, and by Hargrove et al,
Regulatory Peptides, 141:113-119 (2007), the disclosure of which is
incorporated by reference herein. In one embodiment, the term
"GLP-1(7-37) analog" refers to a peptide that has an amino acid
sequence with 1, 2, 3, 4, 5, 6, 7, or 8 amino acid substitutions,
insertions, deletions, or a combination of two or more thereof,
when compared to the amino acid sequence of GLP-1(7-37) (SEQ ID NO:
84). In one embodiment, the GLP-1(7-37) analog is GLP-1(7-36) (SEQ
ID NO: 85). GLP-1(7-37) analogs include the amidated forms, the
acid form, the pharmaceutically acceptable salt form, and any other
physiologically active form of the molecule.
[0041] "N-Terminus conformationally constrained GLP-1 receptor
agonist compounds" refers to compounds in which one, two, three, or
four of the amino acid residues at positions 1-4 at the N-terminus
of "GLP-1 receptor agonist compounds" (e.g., exendins, exendin
analogs, GLP-1, GLP-1 analogs, GLP-1(7-37) (SEQ ID NO: 84),
GLP-1(7-37) analogs) have been modified or substituted with amino
acids (e.g., natural and/or non-natural amino acids),
peptidomimetics, or beta-turn dipetidemimetics. This
substitution(s) or modification(s) to the N-terminus of the parent
GLP-1 receptor agonist compound changes the flexible random coil
structure of this specific region into a more rigid secondary
structure with beta-turn characteristics.
[0042] The glycine residues at positions 2 and 4 at the N-terminus
of exendin-4 may indicate the presence of a .beta.-turn in this
region. In order to produce a conformationally constrained
N-terminus, exendin analogs having a mimetic or other structural
modification that restricted the conformational flexibility of the
His.sup.1 side chain were synthesized. Restricting the flexibility
of the His.sup.1 side chain was hypothesized to provide structural
information about the possible bioactive conformation of GLP-1
receptor agonist compounds and thus enhance GLP-1 receptor binding,
in vivo blood glucose lowering activity, and enzymatic
stability.
[0043] An Ala scan of exendin-4 showed that the Glu.sup.3 residue
was important for biological activity. Additionally, Glu.sup.3 or
Asp.sup.3 are present in many members of the super-family of
glucagon-related peptides, which indicates the importance of an
acidic side chain at that residue.
[0044] It was postulated that the negative charge of Glu.sup.3 or
Asp.sup.3 interacted through an ionic bond with the positive charge
of the His.sup.1 side chain to position the key imidazole ring of
the His.sup.1 side chain in the right space for interaction with
the GLP-1 receptor. It was thus proposed that a .beta.-turn would
be formed by the sequence Gly.sup.2Glu.sup.3Gly.sup.4Thr.sup.5 (SEQ
ID NO: 17) in the super-family of glucagon related peptides, such
as exendin-4 and exendin analogs.
[0045] In order to maintain the negative charge of Glu.sup.3,
thought to be essential for biological activity, 13-turn peptide
mimetics were synthesized to mimic the amino acid residues
Glu.sup.3Gly.sup.4. In one embodiment, the disclosure provides
N-terminus conformationally constrained compounds of Formula
(F):
Xaa.sub.1Xaa.sub.2Xaa.sub.3-Z;
wherein: Xaa.sub.1 is a compound of Formula (1), as described
herein; Xaa.sub.2 is Gly, Ala, dAla, or Aib;
Xaa.sub.3 is:
[0046] ##STR00001## [0047] wherein * indicates a chiral carbon
atom; and R.sub.2 is hydrogen or a C.sub.1-4 alkyl (e.g., methyl,
ethyl); and
Z is:
[0047] [0048] (i) OH; [0049] (ii) NH.sub.2; [0050] (iii)
TFTSDLSKQXaa.sub.14EEEAVRLFIEXaa.sub.25LKN-Z.sub.1 (SEQ ID NO: 18);
[0051] (iv)
TFTSDLSKQXaa.sub.14EEEAVRLFIEXaa.sub.25LKNGGPSSGAPPPS-Z.sub.1 (SEQ
ID NO: 19); [0052] (v)
TFTSDLSKQXaa.sub.14EEEAVRLFIEXaa.sub.25LK-R.sub.10-Z.sub.1 (SEQ ID
NO: 20); or [0053] (vi)
TFTSDVSSYXaa.sub.14EGQAAKEFIAXaa.sub.25LVXaa.sub.28GRXaa.sub.31-Z.sub.1
(SEQ ID NO: 21); [0054] wherein: [0055] Z.sub.1 is OH or NH.sub.2;
[0056] Xaa.sub.14 is Leu or Met; [0057] Xaa.sub.25 is Phe or Trp;
[0058] Xaa.sub.28 is Lys or Arg; [0059] Xaa.sub.31 is Gly or
absent; and [0060] R.sub.10 is QGGPSKEIIS (SEQ ID NO: 22);
QGGPSSGAPPPS (SEQ ID NO: 23); NG; NGG; NGGP (SEQ ID NO: 24); NGGPS
(SEQ ID NO: 25); NGGPSS (SEQ ID NO: 26); NGGPSSG (SEQ ID NO: 27);
NGGPSSGA (SEQ ID NO: 28); NGGPSSGAP (SEQ ID NO: 29); NGGPSSGAPP
(SEQ ID NO: 30); NGGPSSGAPPP (SEQ ID NO: 31); NGGPSSGAPPS (SEQ ID
NO: 32); NGGPSSGAPPSK (SEQ ID NO: 33); NGGPSSGAPPS(K).sub.2-6 (SEQ
ID NO: 34); NGGPSSGAPPPSK (SEQ ID NO: 35); or NK.
[0061] When Z is OH or NH.sub.2, the compounds of Formula (F) are
N-terminus conformationally constrained compounds. When Z is (iii),
(iv), (v) or (vi), the compounds of Formula (F) are N-terminus
conformationally constrained GLP-1 receptor agonist compounds.
[0062] Exemplary compounds of Formula (F) include the compounds in
FIGS. 15A-D and 16A-H, each of which may be optionally amidated at
the C-terminal amino acid residue. The reaction schemes for
preparing the compounds are shown, e.g., in FIGS. 18-20.
[0063] Additional studies were undertaken to restrict the
N-terminus conformation of GLP-1 receptor agonist compounds and it
was unexpectedly discovered that the .beta.-turn in GLP-1 receptor
agonist compounds, such as exendin and exendin analogs, was
provided by His.sup.1Gly.sup.2Glu.sup.3Gly.sup.4 (SEQ ID NO: 36).
Thus, GLP-1 receptor agonist compounds were produced to constrain
or mimic a .beta.-turn defined by residues
His.sup.1Gly.sup.2Glu.sup.3Gly.sup.4 (SEQ ID NO: 36) in exendin-4
and other GLP-1 receptor agonist compounds; or to constrain or
mimic a .beta.-turn defined by residues
His.sup.1Ala.sup.2Glu.sup.3Gly.sup.4 (SEQ ID NO: 37) in GLP-1,
GLP-1 analogs, GLP-1(7-37) (SEQ ID NO: 84), or GLP-1(7-37)
analogs.
[0064] Provided herein are N-terminus conformationally constrained
compounds of Formula (A):
Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4-Z.
[0065] In one embodiment, the disclosure provides the compound of
Formula (A):
Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4-Z;
wherein: [0066] Xaa.sub.1 is a compound of Formula (1):
[0066] ##STR00002## [0067] wherein R.sub.20 and R.sub.21 are each
independently a single bond or a carbon atom; R.sub.23, R.sub.24,
R.sub.25 and R.sub.26 are each independently absent, hydrogen,
hydroxyl, C.sub.1-4 alkyl, carboxyl, or C.sub.1-4 alkoxy; - - - - -
- is a single bond or a double bond; and R.sub.21 is a chiral or
achiral carbon atom; [0068] Xaa.sub.2 is Gly, dAla, Aib, Ala, Val,
NMeAla, a compound of Formula (3), as described herein; or a
compound of Formula (4) and described herein; and Xaa.sub.2 is
absent when Xaa.sub.3 is:
[0068] ##STR00003## [0069] Xaa.sub.3 is Pro; a compound of Formula
(2), as described herein; a compound of Formula (3), as described
herein; a Compound of Formula (4), as described herein;
[0069] ##STR00004## [0070] Xaa.sub.4 is Gly, dAla, or Aib; and
[0071] Z is OH or NH.sub.2. In other embodiments, Xaa.sub.3 is Pro.
In other embodiments, Xaa.sub.2 is dAla, Aib, Ala, Val, NMeAla, a
compound of Formula (3), or a compound of Formula (4).
[0072] In other embodiments, the disclosure provides the compound
of Formula (A):
Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4-Z;
wherein: [0073] Xaa.sub.1 is
[0073] ##STR00005## [0074] Xaa.sub.2 is Gly, dAla, Aib, Ala, Val,
NMeAla, a compound of Formula (3), as described herein; or a
compound of Formula (4), as described herein; and Xaa.sub.2 is
absent when Xaa.sub.3 is:
[0074] ##STR00006## [0075] Xaa.sub.3 is Glu; Pro; a compound of
Formula (2), as described herein; a compound of Formula (3), as
described herein; a Compound of Formula (4), as described
herein;
[0075] ##STR00007## [0076] Xaa.sub.4 is Gly, dAla, or Aib; and
[0077] Z is OH or NH.sub.2.
[0078] Also provided herein are N-terminus conformationally
constrained GLP-1 receptor agonist compounds of Formula
(B)-(E):
TABLE-US-00003 (B) (SEQ ID NO: 1)
Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4TFTSDLSKQXaa.sub.14EEEAVRLFIEXaa.sub.2-
5LKN- Z; (C) (SEQ ID NO: 2)
Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4TFTSDLSKQXaa.sub.14EEEAVRLFIEXaa.sub.2-
5LK- R.sub.10-Z; (D) (SEQ ID NO: 3)
Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4TFTSDLSKQXaa.sub.14EEEAVRLFIEXaa.sub.2-
5LKNGG PSSGAPPPS-Z; (E) (SEQ ID NO: 4)
Xaa.sub.1Xaa.sub.2Xaa.sub.3Xaa.sub.4TFTSDVSSYXaa.sub.14EGQAAKEFIAXaa.sub.2-
5LV Xaa.sub.28GRXaa.sub.31-Z.
The substituents for the compounds of Formula (A), (B), (C), (D),
and (E) are as follows: [0079] Xaa.sub.1 is a compound of Formula
(1), as described herein; [0080] Xaa.sub.2 is Gly; dAla; Aib; Ala;
Val; NMeAla; a compound of Formula (3), as described herein; or a
compound of Formula (4), as described herein; and Xaa.sub.2 is
absent when Xaa.sub.3 is:
[0080] ##STR00008## [0081] Xaa.sub.3 is Pro; Glu; Asp; a compound
of Formula (2), as described herein; a compound of Formula (3), as
described herein; a Compound of Formula (4), as described
herein;
[0081] ##STR00009## [0082] Xaa.sub.4 is Gly, dAla, or Aib; [0083]
Xaa.sub.14 is Leu or Met; [0084] Xaa.sub.25 is Phe or Trp; [0085]
Xaa.sub.28 is Lys or Arg; [0086] Xaa.sub.31 is Gly or absent;
[0087] R.sub.10 is QGGPSKEIIS (SEQ ID NO: 22); QGGPSSGAPPPS (SEQ ID
NO: 23); NG; NGG; NGGP (SEQ ID NO: 24); NGGPS (SEQ ID NO: 25);
NGGPSS (SEQ ID NO: 26); NGGPSSG (SEQ ID NO: 27); NGGPSSGA (SEQ ID
NO: 28); NGGPSSGAP (SEQ ID NO: 29); NGGPSSGAPP (SEQ ID NO: 30);
NGGPSSGAPPP (SEQ ID NO: 31); NGGPSSGAPPS (SEQ ID NO: 32);
NGGPSSGAPPSK (SEQ ID NO: 33); NGGPSSGAPPS(K).sub.2-6 (SEQ ID NO:
34); NGGPSSGAPPPSK (SEQ ID NO: 35); or NK; and [0088] Z is OH or
NH.sub.2.
[0089] The compounds of Formula (A)-(E) may optionally be in the
form of a pharmaceutically acceptable salt.
[0090] The compound of Formula (1) is:
##STR00010##
wherein R.sub.20 and R.sub.21 are each independently a single bond
or a carbon atom; R.sub.23, R.sub.24, R.sub.25 and R.sub.26 are
each independently absent, hydrogen, hydroxyl, C.sub.1-4 alkyl,
carboxyl, amino, or C.sub.1-4 alkoxy; - - - - - - is a single bond
or a double bond; and R.sub.21 is a chiral or achiral carbon
atom.
[0091] In one embodiment for the compound of Formula (1), R.sub.20
and R.sub.21 are each independently a single bond or a carbon atom;
R.sub.23 and R.sub.24 are each independently absent, hydrogen,
hydroxy, a C.sub.1-4 alkyl, carboxyl, or a C.sub.1-4 alkoxy;
R.sub.25 and R.sub.26 are each independently absent, hydrogen,
hydroxy, a C.sub.1-4 alkyl, carboxyl, amino, or a C.sub.1-4 alkoxy;
- - - - - - is a single bond or a double bond; and R.sub.21 is a
chiral or achiral carbon atom.
[0092] In one embodiment for the compound of Formula (1), R.sub.20
and R.sub.21 are each independently a single bond or a carbon atom;
R.sub.23 and R.sub.24 are each independently absent, hydrogen,
hydroxy, methyl, ethyl, or carboxyl; R.sub.25 and R.sub.26 are each
independently absent or hydrogen; - - - - - - is a single bond or a
double bond; and R.sub.21 is a chiral or achiral carbon atom.
[0093] In one embodiment, the compound of Formula (1) is a compound
of Formula (1a), (1b), (1c), (1d), (1e), (1f), (1g), (1h), (1j),
(1k), (1m), or (1n):
##STR00011## ##STR00012##
[0094] In one embodiment, the compound of Formula (1) is a compound
of Formula (1a), (1b), (1c), (1d), (1e), (1f), (1g), (1 h), (1j),
(1k), or (1m).
[0095] In one embodiment, the compound of Formula (1) is a compound
of Formula (1a), (1b), (1c), (1d), (1e), (1f), (1g), (1 h), or
(1k).
[0096] In one embodiment, the compound of Formula (1) is a compound
of Formula (1j) or (1m).
[0097] In one embodiment, the compound of Formula (1) is a compound
of Formula (1n).
[0098] The compounds of Formula (2) and Formula (3) are:
##STR00013##
wherein Y.sub.1 and Z.sub.1 are each independently a single bond, a
carbon, or a sulfur; and W.sub.1, W.sub.2 and W.sub.3 are each
independently selected from hydrogen, C.sub.1-6 alkyl, C.sub.1-6
alkoxy, hydroxyl, and amino; and when one Y.sub.1 or Z.sub.1 is
sulfur, the sulfur may be bonded to two oxygen atoms to form a
sulfonyl group; and - - - - - - is or .
[0099] In one embodiment for the Compounds of Formula (2) and (3),
Y.sub.1 and Z.sub.1 are each independently a single bond, a carbon,
or a sulfur; and W.sub.1, W.sub.2 and W.sub.3 are each
independently selected from hydrogen, C.sub.1-4 alkyl, C.sub.1-4
alkoxy, and amino; and when one Y.sub.1 or Z.sub.1 is sulfur, the
sulfur may be bonded to two oxygen atoms to form a sulfonyl group;
and - - - - - - is or .
[0100] In one embodiment for the Compounds of Formula (2) and (3),
Y.sub.1 and Z.sub.1 are each independently a single bond, a carbon,
or a sulfur; and W.sub.1, W.sub.2 and W.sub.3 are each
independently selected from hydrogen, C.sub.1-4 alkyl, and
C.sub.1-4 alkoxy; and when one Y.sub.1 or Z.sub.1 is sulfur, the
sulfur may be bonded to two oxygen atoms to form a sulfonyl group;
and - - - - - - is or .
[0101] In one embodiment for the Compounds of Formula (2) and (3),
- - - - - - is .
[0102] In one embodiment for the Compounds of Formula (2), Y.sub.1
and Z.sub.1 are each independently a single bond, a carbon, or a
sulfur; and W.sub.1, W.sub.2 and W.sub.3 are each independently
selected from the group consisting of hydrogen, methyl, ethyl, and
propyl; and - - - - - - is .
[0103] In one embodiment for the Compounds of Formula (3), Y.sub.1
and Z.sub.1 are each independently a single bond or carbon; and
W.sub.1, W.sub.2 and W.sub.3 are each independently selected from
the group consisting of hydrogen, methyl, ethyl, and propyl; and -
- - - - - is .
[0104] In one embodiment, the compound of Formula (2) is a compound
of Formula (2Z):
##STR00014##
wherein R.sub.40, R.sub.41, and R.sub.42 are each independently
selected from the group consisting of hydrogen and C.sub.1-4 alkyl
(preferably methyl or ethyl). Exemplary compounds of Formula (2Z)
include compounds of Formula (2d), (2e), (2f), (2g), and (2h)
described below.
[0105] In one embodiment, the compound of Formula (2) is a compound
of Formula (2a), (2b), (2c), (2d), (2e), (2f), (2g), (2h), or
(2j):
##STR00015##
[0106] In one embodiment, the compound of Formula (2) is a compound
of Formula (2d), (2e), (20, (2g), or (2h).
[0107] In one embodiment, the compound of Formula (3) is a compound
of Formula (3a), (3b), or (3c):
##STR00016##
[0108] The compound of Formula (4) is:
##STR00017##
wherein R.sub.30, R.sub.31, and R.sub.32 are each independently
hydrogen or a C.sub.1-4 alkyl; or R.sub.30 and R.sub.31, together
with the nitrogen.sup.1 and the carbon.sup.2, form a 5-membered or
6-membered heterocyclic ring; or R.sub.31 and R.sub.32, together
with the carbon.sup.2, form a 3-, 4-, or 5-membered carbocyclic
ring.
[0109] In one embodiment for the compound of Formula (4), R.sub.30,
R.sub.31, and R.sub.32 are each independently hydrogen, methyl, or
ethyl; or R.sub.30 and R.sub.31, together with the nitrogen.sup.1
and carbon.sup.2, form a 5-membered or 6-membered heterocyclic
ring; or R.sub.31 and R.sub.32, together with the carbon.sup.2,
form a 3-, or 4-membered carbocyclic ring;
[0110] In one embodiment, the compound of Formula (4) is a compound
of Formula (4a), (4b), (4c), (4d), or (4e):
##STR00018##
[0111] In one embodiment for the Compounds of Formula (A)-(F),
Xaa.sub.2 is dAla, Aib, Ala, Val, or NMeAla.
[0112] In one embodiment for the Compounds of Formula (A)-(F),
Xaa.sub.2 is a compound of Formula (3).
[0113] In one embodiment for the Compounds of Formula (A)-(F),
Xaa.sub.2 is a compound of Formula (4).
[0114] In one embodiment for the Compounds of Formula (A)-(F),
Xaa.sub.2 is Gly.
[0115] In one embodiment for the Compounds of Formula (A)-(F),
Xaa.sub.2 is dAla.
[0116] In one embodiment for the Compounds of Formula (A)-(F),
Xaa.sub.2 is dAla or Aib.
[0117] In one embodiment for the Compounds of Formula (A)-(F),
Xaa.sub.3 is Pro.
[0118] In one embodiment for the Compounds of Formula (A)-(F),
Xaa.sub.3 is Glu.
[0119] In one embodiment for the Compounds of Formula (A)-(F),
Xaa.sub.3 is a compound of Formula (2), as described herein.
[0120] In one embodiment for the Compounds of Formula (A)-(F),
Xaa.sub.3 is a compound of Formula (3), as described herein.
[0121] In one embodiment for the Compounds of Formula (A)-(F),
Xaa.sub.2 is absent and Xaa.sub.3 is
##STR00019##
[0122] In one embodiment for the Compounds of Formula (A)-(F),
Xaa.sub.4 is Gly or dAla.
[0123] In one embodiment for the Compounds of Formula (A)-(F), Z is
NH.sub.2.
[0124] For the Compounds of Formula (A)-(F): in one embodiment
R.sub.10 is QGGPSKEIIS (SEQ ID NO: 22); in one embodiment R.sub.10
is NG; in one embodiment R.sub.10 is NGG; in one embodiment
R.sub.10 is NGGP (SEQ ID NO: 24); in one embodiment R.sub.10 is
NGGPS (SEQ ID NO: 25); in one embodiment R.sub.10 is NGGPSS (SEQ ID
NO: 26); in one embodiment R.sub.10 is NGGPSSG (SEQ ID NO: 27); in
one embodiment R.sub.10 is NGGPSSGA (SEQ ID NO: 28); in one
embodiment R.sub.10 is NGGPSSGAP (SEQ ID NO: 29); in one embodiment
R.sub.10 is NGGPSSGAPP (SEQ ID NO: 30); in one embodiment R.sub.10
is NGGPSSGAPPP (SEQ ID NO: 31); in one embodiment R.sub.10 is
NGGPSSGAPPS (SEQ ID NO: 32); in one embodiment R.sub.10 is
NGGPSSGAPPSK (SEQ ID NO: 33); in one embodiment R.sub.10 is
NGGPSSGAPPS(K).sub.2-6 (SEQ ID NO: 34); in one embodiment R.sub.10
is NGGPSSGAPPPSK (SEQ ID NO: 35); and in one embodiment R.sub.10 is
NK; and in one embodiment R.sub.10 is QGGPSSGAPPPS (SEQ ID NO:
23).
[0125] For the Compounds of Formula (A)-(F): in one embodiment
Xaa.sub.14 is Met and Xaa.sub.25 is Trp; in one embodiment
Xaa.sub.14 is Leu and Xaa.sub.25 is Phe; in one embodiment
Xaa.sub.14 is Met and Xaa.sub.25 is Phe; and in one embodiment
Xaa.sub.14 is Leu and Xaa.sub.25 is Trp.
[0126] With respect to the compounds of Formula (D), Xaa.sub.2,
Xaa.sub.3, Xaa.sub.14, and Xaa.sub.25 cannot simultaneously be Gly,
Glu, Met, and Trp, respectively, except when the compound of
Formula (1) is a compound of Formula 1(j) or 1(m). Thus, when
Xaa.sub.2, Xaa.sub.3, Xaa.sub.14, and Xaa.sub.25 are Gly, Glu, Met,
and Trp, respectively, the compound of Formula (D) may be one of
the following:
##STR00020##
[0127] In one embodiment, the N-terminus conformationally
constrained GLP-1 receptor agonist compound may be
Pro.sup.3-exendin-4 (SEQ ID NO: 40); Pro.sup.3,Leu.sup.14-exendin-4
(SEQ ID NO: 41); Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4 (SEQ ID
NO: 42); Pro.sup.3-exendin-4(1-28) (SEQ ID NO: 43);
Pro.sup.3,Leu.sup.14-exendin-4(1-28) (SEQ ID NO: 44);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-28) (SEQ ID NO: 45);
Pro.sup.3-exendin-4(1-36) (SEQ ID NO: 46);
Pro.sup.3,Leu.sup.14-exendin-4(1-36) (SEQ ID NO: 47);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-36) (SEQ ID NO: 48); or
HGPGTFTSDLSKQLEEEAVRLFIEWLKQGGPSKEIIS (SEQ ID NO: 49), each of
which may optionally be amidated and which may optionally be in the
form of a pharmaceutically acceptable salt.
[0128] In one embodiment, the N-terminus conformationally
constrained GLP-1 receptor agonist compound may be
Pro.sup.3-exendin-3 (SEQ ID NO: 50); Pro.sup.3-exendin-4(1-29) (SEQ
ID NO: 51); Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-29) (SEQ ID
NO: 52); Pro.sup.3-exendin-4(1-30) (SEQ ID NO: 53);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-30) (SEQ ID NO: 54);
Pro.sup.3-exendin-4(1-31) (SEQ ID NO: 55);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-31) (SEQ ID NO: 56);
Pro.sup.3-exendin-4(1-32) (SEQ ID NO: 57);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-32) (SEQ ID NO: 58);
Pro.sup.3-exendin-4(1-33) (SEQ ID NO: 59);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-33) (SEQ ID NO: 60);
Pro.sup.3-exendin-4(1-34) (SEQ ID NO: 61);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-34) (SEQ ID NO: 62);
Pro.sup.3-exendin-4(1-35) (SEQ ID NO: 63);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-35) (SEQ ID NO: 64);
Pro.sup.3-exendin-4(1-37) (SEQ ID NO: 65);
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-37) (SEQ ID NO: 66);
Pro.sup.3-exendin-4(1-38) (SEQ ID NO: 67); or
Pro.sup.3,Leu.sup.14,Phe.sup.25-exendin-4(1-38) (SEQ ID NO: 68),
each of which may optionally be amidated and which may optionally
be in the form of a pharmaceutically acceptable salt.
[0129] Examples of the compounds of Formula (A), (B), (C), (D), and
(E) are shown in FIGS. 1B-C, 2A-U, 3A-G, 5B-G, 6A-E, 8A-H, 9A-H,
10A-I, 11A-B, 12, 13, 14A-Q, 15C-D, 16I-L, and 17A-N.
[0130] The N-terminus conformationally constrained compounds (e.g.,
compounds of Formula (A) and (F)) and the N-Terminus
conformationally constrained GLP-1 receptor agonist compounds
(e.g., compounds of Formula (B)-(F)) described herein (collectively
referred to as "the compounds") can optionally be covalently linked
to one or more polymers to provide beneficial biological properties
to the compounds. Such beneficial properties may include conferring
another therapeutic property to the compounds; increasing the in
vivo half life of the compounds; decreasing the rate of clearance
of the compounds by the kidney; decreasing the immunogenicity of
the compounds; decreasing the proteolysis rate of the compounds; or
increasing the stability of the compounds. Exemplary polymers that
can be covalently linked to the compounds include peptides,
polyethylene glycols, albumin, fatty acids, dextran, polyamino
acids, alkyl chains, immunoglobulins, signaling moieties, gelatin,
polyvinyl pyrrolidone, polyvinyl alcohol,
N-(2-hydroxypropyl)-methacrylamide, and the like. In one
embodiment, two or more polymers (e.g., peptides, polyethylene
glycols, albumin, fatty acids, dextran, polyamino acids, alkyl
chains, immunoglobulins, gelatin, polyvinyl pyrrolidone, polyvinyl
alcohol, N-(2-hydroxypropyl)-methacrylamide) are covalently
attached together and linked to the N-terminus conformation
constrained compounds described herein. For example, the two more
polymers that are linked together may be polyethylene glycol(s) and
fatty acid(s) or a peptide, polyethylene glycol(s), and fatty
acids.
[0131] In one embodiment, the compounds are linked to another
peptide to provide additional therapeutic benefits. Such peptides
include amylin, amylin agonist analogs (e.g., amylin analogs that
function as amylin agonists), PYY, PYY analogs, GIP, GIP analogs,
leptin, metraleptin, leptin analogs, metraleptin analogs, and the
like. Hybrid peptides comprising the compounds and another
therapeutic peptide are described, for example, in WO 2005/077072
and WO 2007/022123, the disclosures of which are incorporated by
reference herein.
[0132] In one embodiment, compounds are linked to one, two, or
three polyethylene glycols. In one embodiment, the compounds are
linked to one polyethylene glycol. The polyethylene glycol can have
a molecular weight from about 200 daltons to about 80,000 daltons;
from about 5,000 from about 10,000 daltons to about 60,000 daltons;
from about 10,000 daltons to about 50,000 daltons; or from about
15,000 daltons to about 40,000 daltons. The polyethylene glycol may
be linear or branched.
[0133] In one embodiment, compounds are linked to one or two
polyethylene glycols, where the polyethylene glycol is further
linked to a lipophilic moiety. In one embodiment, the polyethylene
glycol may have a molecular weight from about 200 to about 7,000
daltons or from about 500 to about 5,000 daltons. The lipophilic
moiety may be an alkyl group (e.g., C.sub.1-20 alkyl group;
C.sub.1-10 alkyl group; C.sub.1-6 alkyl group; C.sub.1-4 alkyl
group), a fatty acid (e.g., C.sub.4-28 fatty acid; C.sub.4-20 fatty
acid; C.sub.4-10 fatty acid), cholesteryl, adamantyl, and the like.
The alkyl group may be linear or branched, preferably linear. In
one embodiment, the fatty acid is an acetylated fatty acid or an
esterified fatty acid. The -(polyethylene glycol)-(lipophilic
moiety) may be linked to the compound at a C-terminal amino acid
residue, an N-terminal amino acid residue, an internal amino acid
residue (e.g., an internal Lys amino acid residue), or a
combination thereof (e.g., the compound is linked at the N-terminal
and C-terminal amino acid residues via a lysine residue). Examplary
peptides linked to such groups are shown in Example 20.
[0134] In one embodiment, the compounds are linked to a polyamino
acid. Exemplary polyamino acids include poly-lysine, poly-aspartic
acid, poly-serine, poly-glutamic acid, and the like. The polyamino
acid may be in the D or L form, preferably the L form. The
polyamino acids may comprise from 1 to 12 amino acid residues; from
2 to 10 amino acid residues; or from 2 to 6 amino acid
residues.
[0135] In one embodiment, compounds are linked to a fatty acid. The
fatty acid may be a C.sub.4-C.sub.28 fatty acid chain, a
C.sub.8-C.sub.24 fatty acid chain, or a C.sub.10-C.sub.20 fatty
acid chain. In one embodiment, the fatty acid is an acetylated
fatty acid. In one embodiment, the fatty acid is an esterified
fatty acid.
[0136] In one embodiment, the compounds are linked to albumin. The
albumin may be a recombinant albumin, serum albumin, or recombinant
serum albumin. In another embodiment, the compounds are linked to
an albumin-fatty acid (i.e., an albumin linked to a fatty
acid).
[0137] In one embodiment, the compounds are linked to an
immunoglobulin or an immunoglobulin Fc region. The immunoglobulin
may be IgG, IgE, IgA, IgD, or IgM. In one embodiment, the compounds
are linked to an IgG Fc region or an IgM Fc region. The
immunoglobulin Fc region is (i) the heavy chain constant region
2(C.sub.H2) of an immunoglobulin; (ii) the heavy chain constant
region 3(C.sub.H3) of an immunoglobulin; or (iii) both the heavy
chain constant regions 2(C.sub.H2) and 3(C.sub.H3) of an
immunoglobulin. The immunoglobulin Fc region may further comprise
the hinge region at the heavy chain constant region. Other
embodiments for the immunoglobulin Fc region that can be linked to
exendin analog peptides are described in WO 2008/082274, the
disclosure of which is incorporated by reference herein.
[0138] In one embodiment, the compounds are linked to one or more
signalling moieties. Exemplary signalling moieties include, biotin,
antigens, antibodies, receptors, enzymes, chemiluminescent groups,
photoreactive groups, fluorescent groups, heavy metal-containing
compounds (e.g., ferritin), and the like.
[0139] When the compounds described herein are covalently linked to
one or more polymers, such as those described herein, any linking
group known in the art can be used. The linking group may comprise
any chemical group(s) suitable for linking the peptide to the
polymer. Alternatively, compounds can be directly attached to the
polymer without any linking group. Exemplary linking groups include
amino acids, maleimido groups, dicarboxylic acid groups,
succinimide groups, or a combination of two or more thereof.
Methods for linking peptides to one or more polymers are known in
the art and described, for example, in U.S. Pat. No. 6,329,336;
U.S. Pat. No. 6,423,685; U.S. Pat. No. 6,924,264; WO 2005/077072,
WO 2007/022123, WO 2007/053946; WO 2008/058461; and WO 2008/082274,
the disclosures of which are incorporated by reference herein.
[0140] The compounds described herein may be prepared using
biological, chemical, and/or recombinant DNA techniques that are
known in the art. Exemplary methods are described in U.S. Pat. No.
6,872,700; WO 2007/139941; WO 2007/140284; WO 2008/082274; WO
2009/011544; and US Publication No. 2007/0238669, the disclosures
of which are incorporated herein by reference. Other methods for
preparing the compounds are set forth herein.
[0141] The compounds described herein may be prepared using
standard solid-phase peptide synthesis techniques, such as an
automated or semiautomated peptide synthesizer. Typically, using
such techniques, an alpha-N-carbamoyl protected amino acid and an
amino acid attached to the growing peptide chain on a resin are
coupled at room temperature in an inert solvent (e.g.,
dimethylformamide, N-methylpyrrolidinone, methylene chloride, and
the like) in the presence of coupling agents (e.g.,
dicyclohexylcarbodiimide, 1-hydroxybenzo-triazole, and the like) in
the presence of a base (e.g., diisopropylethylamine, and the like).
The alpha-N-carbamoyl protecting group is removed from the
resulting peptide-resin using a reagent (e.g., trifluoroacetic
acid, piperidine, and the like) and the coupling reaction repeated
with the next desired N-protected amino acid to be added to the
peptide chain. Suitable N-protecting groups are well known in the
art, such as t-butyloxycarbonyl (tBoc) fluorenylmethoxycarbonyl
(Fmoc), and the like. The solvents, amino acid derivatives and
4-methylbenzhydryl-amine resin used in the peptide synthesizer may
be purchased from Applied Biosystems Inc. (Foster City,
Calif.).
[0142] Solid phase peptide synthesis may be carried out with an
automatic peptide synthesizer (Model 430A, Applied Biosystems Inc.,
Foster City, Calif.) using the NMP/HOBt (Option 1) system and tBoc
or Fmoc chemistry (See Applied Biosystems User's Manual for the ABI
430A Peptide Synthesizer, Version 1.3B Jul. 1, 1988, section 6, pp.
49-70, Applied Biosystems, Inc., Foster City, Calif.) with capping.
Boc-peptide-resins may be cleaved with HF (-5.degree. C. to
0.degree. C., 1 hour). The peptide may be extracted from the resin
with alternating water and acetic acid, and the filtrates
lyophilized. The Fmoc-peptide resins may be cleaved according to
standard methods (e.g., Introduction to Cleavage Techniques,
Applied Biosystems, Inc., 1990, pp. 6-12). Peptides may be also be
assembled using an Advanced Chem Tech Synthesizer (Model MPS 350,
Louisville, Ky.).
[0143] Peptides may be purified by RP-HPLC (preparative and
analytical) using a Waters Delta Prep 3000 system. A C4, C8 or C18
preparative column (10.mu., 2.2.times.25 cm; Vydac, Hesperia,
Calif.) may be used to isolate peptides, and purity may be
determined using a C4, C8 or C18 analytical column (5.mu.,
0.46.times.25 cm; Vydac). Solvents (A=0.1% TFA/water and B=0.1%
TFA/CH.sub.3CN) may be delivered to the analytical column at a flow
rate of 1.0 ml/min and to the preparative column at 15 ml/min.
Amino acid analyses may be performed on the Waters Pico Tag system
and processed using the Maxima program. Peptides may be hydrolyzed
by vapor-phase acid hydrolysis (115.degree. C., 20-24 h).
Hydrolysates may be derivatized and analyzed by standard methods
(Cohen et al, The Pico Tag Method: A Manual of Advanced Techniques
for Amino Acid Analysis, pp. 11-52, Millipore Corporation, Milford,
Mass. (1989)). Fast atom bombardment analysis may be carried out by
M-Scan, Incorporated (West Chester, Pa.). Mass calibration may be
performed using cesium iodide or cesium iodide/glycerol. Plasma
desorption ionization analysis using time of flight detection may
be carried out on an Applied Biosystems Bio-Ion 20 mass
spectrometer.
[0144] The compounds described herein may also be prepared using
recombinant DNA techniques using methods known in the art, such as
Sambrook et al., Molecular Cloning: A Laboratory Manual, 2d Ed.,
Cold Spring Harbor (1989). Non-peptide compounds may be prepared by
art-known methods. For example, phosphate-containing amino acids
and peptides containing such amino acids, may be prepared using
methods known in the art, such as described in Bartlett et al,
Biorg. Chem., 14:356-377 (1986).
[0145] The disclosure also provides pharmaceutical compositions
comprising at least one of the N-terminus conformationally
constrained compounds or the N-terminus conformationally
constrained GLP-1 receptor agonist compounds described herein and a
pharmaceutically acceptable carrier. The N-terminus
conformationally constrained compounds or the N-terminus
conformationally constrained GLP-1 receptor agonist compounds can
be present in the pharmaceutical composition in a therapeutically
effective amount and can be present in an amount to provide a
minimum blood plasma level for therapeutic efficacy.
[0146] Pharmaceutical compositions containing the compounds
described herein may be provided for peripheral administration,
such as parenteral (e.g., subcutaneous, intravenous,
intramuscular), topical, nasal, or oral administration. Suitable
pharmaceutically acceptable carriers and their formulation are
described in standard formulation treatises, such as Remington's
Pharmaceutical Sciences by Martin; and Wang et al, Journal of
Parenteral Science and Technology, Technical Report No. 10, Supp.
42:2 S (1988).
[0147] The compounds described herein can be provided in parenteral
compositions for injection or infusion. They can, for example, be
suspended in water; an inert oil, such as a vegetable oil (e.g.,
sesame, peanut, olive oil, and the like); or other pharmaceutically
acceptable carrier. In one embodiment, the compounds are suspended
in an aqueous carrier, for example, in an isotonic buffer solution
at a pH of about 3.0 to 8.0, or about 3.0 to 5.0. The compositions
may be sterilized by conventional sterilization techniques or may
be sterile filtered. The compositions may contain pharmaceutically
acceptable auxiliary substances as required to approximate
physiological conditions, such as pH buffering agents. Useful
buffers include for example, acetic acid buffers. A form of
repository or "depot" slow release preparation may be used so that
therapeutically effective amounts of the preparation are delivered
into the bloodstream over many hours or days following subcutaneous
injection, transdermal injection or other delivery method. The
desired isotonicity may be accomplished using sodium chloride or
other pharmaceutically acceptable agents such as dextrose, boric
acid, sodium tartrate, propylene glycol, polyols (such as mannitol
and sorbitol), or other inorganic or organic solutes. Sodium
chloride is preferred particularly for buffers containing sodium
ions.
[0148] The compounds can also be formulated as pharmaceutically
acceptable salts (e.g., acid addition salts) and/or complexes
thereof. Pharmaceutically acceptable salts are non-toxic salts at
the concentration at which they are administered. Pharmaceutically
acceptable salts include acid addition salts such as those
containing sulfate, hydrochloride, phosphate, sulfamate, acetate,
citrate, lactate, tartrate, methanesulfonate, ethanesulfonate,
benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and
quinate. Pharmaceutically acceptable salts can be obtained from
acids such as hydrochloric acid, sulfuric acid, phosphoric acid,
sulfamic acid, acetic acid, citric acid, lactic acid, tartaric
acid, malonic acid, methanesulfonic acid, ethanesulfonic acid,
benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic
acid, and quinic acid. Such salts may be prepared by, for example,
reacting the free acid or base forms of the product with one or
more equivalents of the appropriate base or acid in a solvent or
medium in which the salt is insoluble, or in a solvent such as
water which is then removed in vacuo or by freeze-drying or by
exchanging the ions of an existing salt for another ion on a
suitable ion exchange resin.
[0149] Carriers or excipients can also be used to facilitate
administration of the compounds. Examples of carriers and
excipients include calcium carbonate, calcium phosphate, various
sugars such as lactose, glucose, or sucrose, or types of starch,
cellulose derivatives, gelatin, vegetable oils, polyethylene
glycols and physiologically compatible solvents.
[0150] If desired, solutions of the above compositions may be
thickened with a thickening agent such as methyl cellulose. They
may be prepared in emulsified form, either water in oil or oil in
water. Any of a wide variety of pharmaceutically acceptable
emulsifying agents may be employed including, for example, acacia
powder, a non-ionic surfactant (such as a Tween), or an ionic
surfactant (such as alkali polyether alcohol sulfates or
sulfonates, e.g., a Triton).
[0151] Compositions may be prepared by mixing the ingredients
following generally accepted procedures. For example, the selected
components may be simply mixed in a blender or other standard
device to produce a concentrated mixture which may then be adjusted
to the final concentration and viscosity by the addition of water
or thickening agent and possibly a buffer to control pH or an
additional solute to control tonicity.
[0152] The therapeutically effective amount of the compounds
described herein to treat the diseases described herein will
typically be from about 0.01 .mu.g to about 5 mg; about 0.1 .mu.g
to about 2.5 mg; about 1 .mu.g to about 1 mg; about 1 .mu.g to
about 50 .mu.g; or about 1 .mu.g to about 25 .mu.g. Alternatively,
the therapeutically effective amount of the GLP-1 receptor agonist
compounds may be from about 0.001 .mu.g to about 100 .mu.g based on
the weight of a 70 kg patient; or from about 0.01 .mu.g to about 50
.mu.g based on the weight of a 70 kg patient. These therapeutically
effective doses may be administered once/day, twice/day,
thrice/day, once/week, biweekly, or once/month, depending on the
formulation. The exact dose to be administered is determined, for
example, by the formulation, such as an immediate release
formulation or an extended release formulation. For transdermal,
nasal or oral dosage forms, the dosage may be increased from about
5-fold to about 10-fold.
[0153] The compounds described herein and pharmaceutical
compositions comprising the compounds are useful for treating
diabetes. The diabetes can be Type I diabetes, Type II diabetes, or
gestational diabetes. The methods for treating diabetes provide
administering to a patient in need thereof a therapeutically
effective amount of one or more of the N-terminus conformationally
constrained compounds or the N-terminus conformationally
constrained GLP-1 receptor agonist compounds described herein to
treat diabetes in the patient.
[0154] The compounds described herein and pharmaceutical
compositions comprising the compounds are useful for treating
insulin resistance and stimulating insulin release. The methods for
treating insulin resistance provide administering to a patient in
need thereof a therapeutically effective amount of one or more of
the N-terminus conformationally constrained compounds or the
N-terminus conformationally constrained GLP-1 receptor agonist
compounds described herein to treat insulin resistance in the
patient. The methods for treating stimulating insulin release
provide administering to a patient in need thereof a
therapeutically effective amount of one or more of the N-terminus
conformationally constrained compounds or the N-terminus
conformationally constrained GLP-1 receptor agonist compounds
described herein to stimulate insulin release in the patient.
[0155] The compounds described herein and pharmaceutical
compositions comprising the compounds are useful for treating
postprandial hyperglycemia. The methods for treating postprandial
hyperglycemia provide administering to a patient in need thereof a
therapeutically effective amount of one or more of the N-terminus
conformationally constrained compounds or the N-terminus
conformationally constrained GLP-1 receptor agonist compounds
described herein to treat postprandial hyperglycemia in the
patient.
[0156] The compounds described herein and pharmaceutical
compositions comprising the compounds are useful for lowering blood
glucose levels and lowering HbA1c levels. The methods for lowering
blood glucose levels provide administering to a patient in need
thereof a therapeutically effective amount of one or more of the
N-terminus conformationally constrained compounds or the N-terminus
conformationally constrained GLP-1 receptor agonist compounds
described herein to lower blood glucose levels in the patient. In
one embodiment, the blood glucose levels can be fasting blood
glucose levels. The methods for lowering HbA1c levels provide
administering to a patient in need thereof a therapeutically
effective amount of one or more of the N-terminus conformationally
constrained compounds or the N-terminus conformationally
constrained GLP-1 receptor agonist compounds described herein to
lower HbA1c levels in the patient. HbA1c levels are generally a
long-term measure of a patient's blood glucose levels.
[0157] The compounds described herein and pharmaceutical
compositions comprising the compounds are useful for reducing
gastric motility and delaying gastric emptying. The methods for
reducing gastric motility provide administering to a patient in
need thereof a therapeutically effective amount of one or more of
the N-terminus conformationally constrained compounds or the
N-terminus conformationally constrained GLP-1 receptor agonist
compounds described herein to reduce gastric motility in the
patient. The methods for delaying gastric emptying provide
administering to a patient in need thereof a therapeutically
effective amount of one or more of the N-terminus conformationally
constrained compounds or the N-terminus conformationally
constrained GLP-1 receptor agonist compounds described herein to
delay gastric emptying in the patient.
[0158] The compounds described herein and pharmaceutical
compositions comprising the compounds are useful for reducing food
intake, reducing appetite, increasing satiety, and reducing weight.
The methods for reducing food intake provide administering to a
patient in need thereof a therapeutically effective amount of one
or more of the N-terminus conformationally constrained compounds or
the N-terminus conformationally constrained GLP-1 receptor agonist
compounds described herein to reduce food intake in the patient.
The methods for reducing appetite provide or increasing satiety
administering to a patient in need thereof a therapeutically
effective amount of one or more of the N-terminus conformationally
constrained compounds or the N-terminus conformationally
constrained GLP-1 receptor agonist compounds described herein to
reduce appetite in the patient. The methods for treating reducing
weight provide administering to a patient in need thereof a
therapeutically effective amount of one or more of the N-terminus
conformationally constrained compounds or the N-terminus
conformationally constrained GLP-1 receptor agonist compounds
described herein to reduce weight in the patient. In the methods
described herein, the patient may be in need of a reduced intake in
food, of a reduced appetite, or of reduced weight. In other methods
described herein, the patient may be desirous of having a reduced
intake in food, of having a reduced appetite, or of having a
reduced weight. The patient may be of any weight, and can be
overweight or obese.
[0159] The compounds described herein and pharmaceutical
compositions comprising the compounds are useful for treating
overweight and obesity. The methods for treating overweight provide
administering to a patient in need thereof a therapeutically
effective amount of one or more of the N-terminus conformationally
constrained compounds or the N-terminus conformationally
constrained GLP-1 receptor agonist compounds described herein to
treat overweight in the patient. The methods for treating obesity
provide administering to a patient in need thereof a
therapeutically effective amount of one or more of the N-terminus
conformationally constrained compounds or the N-terminus
conformationally constrained GLP-1 receptor agonist compounds
described herein to treat obesity in the patient.
[0160] The disclosure also provides drug delivery devices having at
least one therapeutically effective dose of the compounds described
herein or the pharmaceutical composition containing the compounds
described herein. The drug delivery devices can be single or
multiple-use vials, single or multiple-use pharmaceutical pens,
single or multiple-use cartridges, and the like. In one embodiment,
the drug delivery devices contain the compounds or pharmaceutical
compositions described herein in amounts capable of providing a
patient with from about 7 to about 40 doses or enough doses to last
about one week or about one month.
EXAMPLES
[0161] The following examples are for purposes of illustration only
and are not intended to limit the scope of the claims.
Example 1
Preparation of Compound in FIG. 16A
[0162] A calculated 100 .mu.mol of Fmoc-Ser(OtBu)-Wang resin was
weighed into a reaction vessel in a Symphony peptide synthesizer,
and the peptide elongation was carried out following standard Fmoc
peptide synthesis protocol up to residue Thr.sup.5. The resulting
peptide-resin intermediate (0.3 g, 0.0927 mmol) was swollen in
dimethylformamide (DMF) and to the slurry was added compound 7
(0.110 g, 2.2 eq), followed by O-(benzotriazol-1-yl)-N,N,N',N'
tetramethyluronium hexafluorophosphate (HBTU) (0.035 g, 2.2 eq),
N-hydroxybenzotriazole (HOBt) (0.03 g, 2.2 eq) and methylmorpholine
(NMM) (0.04 mL, 4.4 eq). After 3 hours, the resin was washed with
DMF 6.times., treated with 20% piperidine in DMF 2.times.25 min and
washed with DMF 6.times.. The above cycle was repeated with
Fmoc-Ala-OH and Fmoc-His(Trt)-OH followed by cleavage of the
peptide from the resin with 10 ml TFA/H.sub.2O/PhOH/TIPS (95:2:2:1)
(TFA is trifluoroacetic acid; TIPS is triisopropylsilyl),
precipitated by methyl-tert-Butyl ether and the obtained residue
applied to a reverse-phase high performance liquid chromatography
(HPLC) column (C.sub.18, 20-50% CH.sub.3CN in 0.1% TFA/H.sub.2O
over 30 min gradient) to afford the titled compound as a white
powder (16.4 mg, 6%): Retention time in reverse phase-high
performance liquid chromatography (RP-HPLC) (C.sub.18, 5-75%
CH.sub.3CN in 0.1% TFA/H.sub.2O over 15 min) is 9.78 min;
Calculated mass for C.sub.189H.sub.294N.sub.48O.sub.60S (M+H).sup.+
4231.84, found by liquid chromatography/mass spectrometry (LC-MS)
1411.3 (M+3H).sup.3+, 1059.6 (M+4H).sup.4+, 2117.2
(M+2H).sup.2+.
Example 2
Preparation of Compound in FIG. 16B
[0163] A calculated 100 .mu.mol of Fmoc-Ser(OtBu)-Wang resin was
weighed into a reaction vessel in a Symphony peptide synthesizer,
and the peptide elongation was carried out following standard Fmoc
peptide synthesis protocol up to residue Thr.sup.5. The resulting
peptide-resin intermediate (0.3 g, 0.0927 mmol) was swollen in DMF
and to the slurry was added compound 24 (0.122 g, 2.2 eq), followed
by HBTU (0.035 g, 2.2 eq), HOBt (0.03 g, 2.2 eq) and NMM (0.04 mL,
4.4 eq). After 3 hours, the resin was washed with DMF 6.times.,
treated with 20% piperidine in DMF 2.times.25 min and washed with
DMF 6.times.. The above cycle was repeated with Fmoc-His(Trt)-OH
followed by cleavage of the peptide from the resin with 10 ml
TFA/H.sub.2O/PhOH/TIPS (95:2:2:1), precipitated by
methyl-tert-Butyl ether. The obtained crude peptide was dissolved
in 1.5 mL of MeOH:ACN (1:1) (ACN is acetonitrile), followed by
addition of 2M LiOH (0.6 mL) and the reaction stirred at RT for 6
h. The crude was dissolved and applied to a reverse-phase HPLC
column (C.sub.18, 20-50% CH.sub.3CN in 0.1% TFA/H.sub.2O over 30
min gradient) to afford the titled compound as a white powder (15
mg, 6%): Retention time in RP-HPLC (C.sub.18, 5-75% CH.sub.3CN in
0.1% TFA/H.sub.2O over 15 min) is 9.82 min; Calculated mass for
C.sub.188H.sub.294N.sub.48O.sub.60 (M+H).sup.+ 4186.72, found by
LC-MS 1396.7 (M+3H).sup.3+, 1048.6 (M+4H).sup.4+, 2114.2
(M+2H).sup.2+.
Example 3
Preparation of Compound in FIG. 16C
[0164] A calculated 100 .mu.mol of Fmoc-Ser(OtBu)-Wang resin was
weighed into a reaction vessel in a Symphony peptide synthesizer,
and the peptide elongation was carried out following standard Fmoc
peptide synthesis protocol up to residue Thr.sup.5. The resulting
peptide-resin intermediate (0.3 g, 0.0927 mmol) was swollen in DMF
and to the slurry was added compound 18 (0.131 g, 2.2 eq), followed
by HBTU (0.035 g, 2.2 eq), HOBt (0.03 g, 2.2 eq) and NMM (0.04 mL,
4.4 eq). After 3 hours, the resin was washed with DMF 6.times.,
treated with 20% piperidine in DMF 2.times.25 min and washed with
DMF 6.times.. The above cycle was repeated with Fmoc-His(Trt)-OH
followed by cleavage of the peptide from the resin with 10 ml
TFA/H.sub.2O/PhOH/TIPS (95:2:2:1), precipitated by
methyl-tert-Butyl ether. The obtained crude peptide was dissolved
in 1.5 mL of MeOH:ACN (1:1), followed by addition of 2M LiOH (0.6
mL) and the reaction stirred at RT for 6 h. The crude was dissolved
and applied to a reverse-phase HPLC column (C.sub.18, 20-50%
CH.sub.3CN in 0.1% TFA/H.sub.2O over 30 min gradient) to afford the
titled compound as a white powder (19.7 mg, 8%): Retention time in
RP-HPLC (C.sub.18, 5-75% CH.sub.3CN in 0.1% TFA/H.sub.2O over 15
min) is 8.58 min; Calculated mass for
C.sub.189H.sub.294N.sub.48O.sub.605 (M+H).sup.+ 4230.80, found by
LC-MS 1411. (M+3H).sup.3+, 1059.6 (M+4H).sup.4+, 2117.2
(M+2H).sup.2+.
Example 4
Preparation of Compound in FIG. 16E
[0165] The synthesis of this compound was accomplished following
the same experimental procedure as described for Example 3. The
only difference was the sequence of the peptide-resin intermediate,
starting with Rink-amide resin. The crude was dissolved and applied
to a reverse-phase HPLC column (C.sub.18, 20-50% CH.sub.3CN in 0.1%
TFA/H.sub.2O over 30 min gradient) to afford the titled compound as
a white powder (15.7 mg, 7%): Retention time in RP-HPLC (C.sub.18,
5-75% CH.sub.3CN in 0.1% TFA/H.sub.2O over 15 min) is 8.25 min;
Calculated mass for C.sub.188H.sub.286N.sub.48O.sub.60S (M+H).sup.+
4238.74, found by LC-MS 1414.8 (M+3H).sup.3+, 1061.6 (M+4H).sup.4+,
2121.2 (M+2H).sup.2+.
Example 5
Preparation of Compound in FIG. 16D
[0166] A calculated 100 .mu.mol of Fmoc-Ser(OtBu)-Wang resin was
weighed into a reaction vessel in a Symphony peptide synthesizer,
and the peptide elongation was carried out following standard Fmoc
peptide synthesis protocol up to residue Thr.sup.5. The resulting
peptide-resin intermediate (0.3 g, 0.0927 mmol) was swollen in DMF
and to the slurry was added compound 11 (0.100 g, 2.2 eq), followed
by HBTU (0.035 g, 2.2 eq), HOBt (0.03 g, 2.2 eq) and NMM (0.04 mL,
4.4 eq). After 3 h, the resin was washed with DMF 6.times., treated
with 20% piperidine in DMF 2.times.25 min and washed with DMF
6.times.. The above cycle was repeated with Fmoc-Ala-OH and
Fmoc-His(Trt)-OH followed by cleavage of the peptide from the resin
with 10 ml TFA/H.sub.2O/PhOH/TIPS (95:2:2:1), precipitated by
methyl-tert-Butyl ether and the obtained residue applied to a
reverse-phase HPLC column (C.sub.18, 20-50% CH.sub.3CN in 0.1%
TFA/H.sub.2O over 30 min gradient) to afford the titled compound as
a white powder (20.3 mg, 10%): Retention time in RP-HPLC (C.sub.18,
5-75% CH.sub.3CN in 0.1% TFA/H.sub.2O over 15 min) is 9.74 min;
Calculated mass for C.sub.188H.sub.294N.sub.48O.sub.60 (M+H).sup.+
4186.72, found by LC-MS 1396.7 (M+3H).sup.3+, 1048.6 (M+4H).sup.4+,
2114.2 (M+2H).sup.2+.
Example 6
Preparation of Compound in FIG. 16F
[0167] A calculated 100 .mu.mol of Fmoc-Ser(OtBu)-Wang resin was
weighed into a reaction vessel in a Symphony peptide synthesizer,
and the peptide elongation was carried out following standard Fmoc
peptide synthesis protocol up to residue Thr.sup.5. The resulting
peptide-resin intermediate (0.3 g, 0.0927 mmol) was swollen in DMF
and to the slurry was added compound 21 (0.125 g, 2.2 eq), followed
by HBTU (0.035 g, 2.2 eq), HOBt (0.03 g, 2.2 eq) and NMM (0.04 mL,
4.4 eq). After 3 h, the resin was washed with DMF 6.times., treated
with 20% piperidine in DMF 2.times.25 min and washed with DMF
6.times.. The above cycle was repeated with Fmoc-His(Trt)-OH
followed by cleavage of the peptide from the resin with 10 ml
TFA/H.sub.2O/PhOH/TIPS (95:2:2:1), precipitated by
methyl-tert-Butyl ether. The obtained crude peptide was dissolved
in 1.5 mL of MeOH:ACN (1:1), followed by addition of 2M LiOH (0.6
mL) and the reaction stirred at RT for 6 h. The crude was dissolved
and applied to a reverse-phase HPLC column (C.sub.18, 20-50%
CH.sub.3CN in 0.1% TFA/H.sub.2O over 30 min gradient) to afford the
titled compound as a white powder (8 mg, 4%): Retention time in
RP-HPLC (C.sub.18, 5-75% CH.sub.3CN in 0.1% TFA/H.sub.2O over 15
min) is 7.93 min; Calculated mass for
C.sub.189H.sub.296N.sub.48O.sub.60 (M+H).sup.+ 4200.75, found by
LC-MS 1401.8 (M+3H).sup.3+, 1051.6 (M+4H).sup.4+, 2102.2
(M+2H).sup.2+.
Example 7
Preparation of Compound in FIG. 16G
[0168] The synthesis of this compound was accomplished following
the same experimental procedure as described for Example 3. The
only difference was the sequence of the peptide-resin intermediate.
The crude was dissolved and applied to a reverse-phase HPLC column
(C.sub.18, 20-50% CH.sub.3CN in 0.1% TFA/H.sub.2O over 30 min
gradient) to afford the titled compound as a white powder (27.4 mg,
18%): Retention time in RP-HPLC (C.sub.18, 5-75% CH.sub.3CN in 0.1%
TFA/H.sub.2O over 15 min) is 8.25 min; Calculated mass for
C.sub.153H.sub.228N.sub.40O.sub.47S (M+H).sup.+ 3411.83, found by
LC-MS 1138.6 (M+3H).sup.3+, 854.5 (M+4H).sup.4+, 1707.9
(M+2H).sup.2+.
Example 8
Preparation of (5,5)-Glu-Gly-OH as shown in FIG. 18
[0169] Preparation of Boc-Asp(OBn)-OMe: Boc-Asp(OBn)-OH 2.4 g (1
equiv, 7.45 mmol) was dissolved in 17 mL of dry DMF in a 100 mL
round-bottom flask. Finely ground K.sub.2CO.sub.3 (1.5 g, 11 mmol)
was added to the solution to form a suspension. The mixture was
cooled to 0.degree. C. in an ice-bath over five minutes. MeI (1 mL,
15 mmol) was then added to the mixture over 20 seconds under a
positive flow of nitrogen. A yellow color developed within 30 min.
The resulting mixture was stirred for 3 hours. The ice-bath was
removed and 25 mL of water were added and the mixture left standing
at room temperature 2 hours. The mixture was then treated with 30
mL of water and extracted with 3.times.25 mL AcOEt. The organics
were washed with saturated NaHCO.sub.3 1.times., brine 3.times.,
dried over Na.sub.2SO.sub.4 filtered and concentrated to yield a
yellow oil. This material was passed through a short silica column
(eluting w/ AcOEt), after concentration of the pure fractions 2.42
g of Boc-Asp(OBn)-OMe as a yellow oil was obtained (98% yield).
.sup.1H NMR (DMSO d6, 500 mHz): .delta. 7.36 (m, 5H), 5.10 (s, 2H),
4.40 (q, 1H), 3.6 (s, 3H), 2.80 (dd, 1H), 2.72 (dd, 1H), 1.38 (s,
9H). LCMS (C.sub.18, 2-98% CH.sub.3CN in 0.1% TFA/H.sub.2O over 6
min); Calculated mass for C.sub.17H.sub.23NO.sub.6 (M+H).sup.+
338.23, found by LC-MS 338.2.
[0170] Preparation of Compound 1 in FIG. 18: Boc-Asp(OBn)-OMe (26.4
g, 78.3 mmol) was dissolved in a 500 mL round-bottom flask with 110
mL of dry THF and the mixture cooled at negative 42.degree. C. To
this mixture was added lithium bis(trimethylsilyl)amide (LiHMDS)
(173 mL, 1 M solution, 2.2 eq). This solution was stirred under a
gentle argon flow for 45 min followed by slow addition (via
syringe) of tert-butyl bromo acetate (14.5 mL, 1.25 eq). Thin layer
chromatography (TLC) (Hex:AcOEt, 8/2) showed after 4 h>95% of
expected product. The reaction was quenched by addition of
saturated NH.sub.4Cl (70 mL). The mixture was evaporated and the
residue re-dissolved with 100 mL of dichloromethane (DCM). The
emulsion formed was separated by standing overnight. The organics
were collected and washed with saturated NH.sub.4Cl 2.times., brine
1.times., dried over Na.sub.2SO.sub.4, filtered and concentrated to
give Compound 1 as a red orange oil. Flash chromatography
(Hex:AcOEt, 7:3) gave 27.4 g of a yellow oil (78% yield). .sup.1H
NMR (DMSO d6, 500 mHz): .delta. 7.35 (m, 5H), 5.08 (s, 2H), 4.57
(dd, 1H), 4.05 (m, 1H), 3.52 (s, 3H), 1.39 (s, 9H), 1.34 (s, 9H).
LCMS (C.sub.18, 2-98% CH.sub.3CN in 0.1% TFA/H.sub.2O over 6 min);
Calculated mass for C.sub.23H.sub.33NO.sub.8 (M+H).sup.+ 452.23,
found by LC-MS 452.2.
[0171] Preparation of Compound 2 in FIG. 18. Compound 2 is
tert-butyl-(1S,2R)-2-[(carboxy)-3-tert-butoxycarbonyl)-1-metoxhycarbonyl)-
]propylcarbamate. Compound 1 (5.8 g, 12.8 mmol) was dissolved in 30
mL of a 6:4 mixture of MeOH/THF. Argon was bubbled in the catalyst
for 5 minutes, followed by incorporation of two hydrogen balloons
attached via syringe to the reaction flask. After 4 hours, LCMS
shows complete transformation. The crude mixture was filtrated
through celite and concentrated to yield 5.25 g of Compound 2 as an
orange oil which was used without further purification in the next
step. Calculated mass for C.sub.16H.sub.27NO.sub.8 (M+H).sup.+
362.23, found by LC-MS 362.2.
[0172] Preparation of Compound 3 in FIG. 18. Compound 3 is
tert-butyl-(1S,2R)-2-[(benzylthio)-carbonyl)-3-tert-butoxycarbonyl)-1-met-
oxhycarbonyl)]propylcarbamate. Compound 2 (2.1 g, 5.8 mmol) was
dissolved with DCM (7 mL). To this clear mixture was added
ethylthiol (0.4 g, 1.1 eq) and 4-dimethylaminopyridine (DMAP) (0.07
g, 0.1 eq). To the clear solution was added dicyclohexyl
carbodiimide (DCC) (1.3 g, 1.1 eq) as a solid and the mixture was
stirred at room temperature for 5 hours. The mixture was diluted
with DCM (40 mL) and washed with 1N HCl (2.times.), dried over
Na.sub.2SO.sub.4, filtered and concentrated to give 2.15 g of
Compound 3 as a yellow oil, which was used without further
purification in the next step. Calculated mass for
C.sub.18H.sub.31NO.sub.7S (M+H).sup.+ 406.13, found by LC-MS
406.2.
[0173] Preparation of Compound 4 in FIG. 18. Compound 4 is
tert-butyl-(1S,2R)-3-(tert-butoxcarbonyl)-1-(methoxycarbonyl)-2-formylpro-
pylcarbamate. To Compound 3 (5.9 g, 14.5 mmol) and Pd--C 10% wt
(0.35 g) were added acetone (36 mL) and the mixture cooled down to
about 4-8.degree. C. To this mixture was added drop wise, under
positive flow of Argon, triethylsilyl (TES) (11.5 mL, 5 eq). After
addition of TES the mixture was kept at 10-15.degree. C. After 3.5
hours LCMS showed no more starting material. The mixture was
filtrated through celite, and the solution concentrated to give 6.6
g of Compound 4 as a green oil which was used without further
purification in the next step. Calculated mass for
C.sub.16H.sub.27NO.sub.7 (M+H).sup.+ 346.13, found by LC-MS
346.2.
[0174] Preparation of Compound 5 in FIG. 18. Compound 5 is
methyl-[3S,4R,8R]-1-Aza-3-tert-butoxycarbonyl-4-(tert-butoxycarbonyl)meth-
yl)-2-oxo-6-thiabicyclic[3.3.0]-octane-8-carboxylate. To Compound 4
(1.3 g, 3.76 mmol), L-Cys-OH--HCl (0.98 g, 1.5 eq) and 4.degree. A
molecular sieves (2g) was added dry pyridine (10 mL) and the
mixture stirred, under argon, at room temperature for 4 hours in
high pressure vessel. After this time, 3.5 mL more of pyridine were
added and the reaction was stirred at 50.degree. C. for 5 days.
After this time, the crude mixture was filtered through celite, the
solution was re-dissolved in AcOEt and washed with 2N HCl 2.times.,
dried over Na.sub.2SO.sub.4, filtered and concentrated to yield 1.2
g of Compound 5 as a yellowish semisolid, which was used without
further purification in the next step. Calculated mass for
C.sub.19H.sub.30N.sub.2O.sub.7S (M+H).sup.+ 431.13, found by LC-MS
431.2.
[0175] Preparation of Compound 6 in FIG. 18. Compound 6 is
[3S,4R,8R]-1-Aza-3-amino-4-(tert-butoxycarbonyl)methyl)-2-oxo-6-thiabicyc-
lic[3.3.0]-octane-8-carboxylate. Crude Compound 5 was treated with
10 mL of a 50% TFA-DCM mixture at 0.degree. C. The mixture was let
to warm up at 10.degree. C. and stirred for 2.5 hours. The mixture
is then concentrated and the residue re-dissolved with 5 mL of a 2M
LiOH solution and stirred at room temperature for 2.5 hours. LCMS
analysis showed complete transformation to Compound 6. The reaction
was concentrated and the residue passed through a short column
packed with ion-exchange resin (H.sup.+, Dowex), eluting with 1:1
MeOH/H.sub.2O. The residue was concentrated and then lyophilized to
give 1.8 g of crude Compound 6 as a yellow semisolid, which was
used without further purification in the next step. Calculated mass
for C.sub.13H.sub.20N.sub.2O.sub.5S (M+H).sup.+ 317.13, found by
LC-MS 317.2.
[0176] Preparation of Compound 7 in FIG. 18. Compound 7 is the
(5,5)-Glu-Gly bicylic dipeptide mimetic. Compound 7 is also
referred to as
[3S,4R,8R]-1-Aza-3-fluorenylmethyl-carbonyl-4-(tert-butoxycarbonyl)met-
hyl)-2-oxo-6-thiabicyclic[3.3.0]-octane-8-carboxylate. Crude
Compound 6 (1.2 g, 3.8 mmol) was dissolved in 17 mL of dry DCM. To
this solution was added FmocOSu (1.8 g, 1.4 eq) followed by
N,N-diisopropylethylamine (DIEA) (1.3 mL, 2 eq). The reaction was
stirred at room temperature for 3 hours. To the mixture was added
50 mL of DCM and washed with 2M HCl 2.times., brine 1.times., dried
over Na.sub.2SO.sub.4, filtered and concentrated to give 1.42 g of
a yellow oil. Purification by flash chromatography using an
increasing polarity solvent gradient (Hex:AcOEt 1:1 to DCM:MeOH
9:1) gave 0.150 g of pure Compound 7. Calculated mass for
C.sub.28H.sub.30N.sub.2O.sub.7S (M+H).sup.+ 539.13, found by LC-MS
539.2.
Example 9
Preparation of Compound 11 in FIG. 19
[0177] Compound 9 is
1-Aza-3-amino-tert-butoxylcarbonyl-4-(tert-butoxycarbonyl)methyl)-2-oxo-1-
-methoxyacetyl. Compound 4 was prepared as described above. A
solution of Compound 4 (preparation described in Example 8) (4.1 g,
12 mmol) and the HCl salt of NH.sub.2-Gly-OMe (1.66 g, 1.1 eq) in
20 mL of DMF were stirred at room temperature. To this mixture was
added NaBH(OAc).sub.3 (5.0 g, 2 eq) dissolved in 18 mL of DMF.
After 1 hour LCMS shows complete transformation to the desired
secondary amine 8. Calculated mass for
C.sub.19H.sub.34N.sub.2O.sub.8 (M+H).sup.+ 419.1, found by LC-MS
419.2. To this crude mixture was added AcOEt (80 mL), washed with
sat. NaHCO.sub.3 3.times., water 1.times., brine 1.times., dried
over Na.sub.2SO.sub.4, filtered and concentrated to give 3.9 g of a
crude yellow oil. LCMS of this material showed that the five-member
ring lactam (Compound 9) was formed during work-up. The residue was
concentrated to give 3.9 g of crude Compound 9 as a yellow oil,
which was used without further purification in the next step.
Calculated mass for C.sub.18H.sub.30N.sub.2O.sub.7 (M+H).sup.+
387.1, found by LC-MS 387.2.
[0178] Preparation of Compound 10 in FIG. 19. Compound 10 is
1-amino-4-(tert-butoxy-carbonyl)methyl)-2-oxo-1-methoxyacetyl.
Crude Compound 9 (3.8 g) was cooled at 10.degree. C. in an
ice-water bath. To this stirred mixture was added in a drop wise
manner 15 mL of a 50% solution of TFA in DCM. The mixture was
stirred at that temperature for 2 h. LCMS showed a selective N-Boc
deprotection. The mixture was concentrated to yield crude compound
10 as clear semisolid, which was used without further purification
in the next step. Calculated mass for
C.sub.13H.sub.22N.sub.2O.sub.5 (M+H).sup.+ 287.1, found by LC-MS
287.2.
[0179] Preparation of Compound 11 in FIG. 19. Compound 11 is a
.gamma.-lactam-Glu-Gly bicyclic dipeptide mimetic which is
1-Aza-3-aminofluorenylmethylcarbonyl-4-(tert-butoxycarbonyl)methyl)-2-oxo-
-1-acetylcarboxylate. Crude Compound 10 (2.8 g, 9.8 mmol) was
dissolved in 8 mL of a 1:1 mixture of dioxane/MeOH at room
temperature. To this mixture was added 15 mL of a 2M LiOH (2.8 eq)
and the mixture stirred at room temperature for 3 hours. The
mixture was then concentrated and passed trough a short column of
Dowex H.sup.+ ion-exchange resin. The pooled fractions containing
M+1=273 by LCMS were collected and lyophilized. This crude material
was then dissolved in DCM (40 mL) followed by addition of DIEA (3.5
mL, 2 eq) and FmocOSu (3.9 g, 1.2 eq). The mixture was stirred at
room temperature for 3 hours. LCMS analysis shows no more starting
material, thus to the reaction was added AcOEt (60 mL), washed with
sat. NaHCO.sub.3 3.times., water 1.times., brine 1.times., dried
over Na.sub.2SO.sub.4, filtered and concentrated to give 2.5 g of a
crude Compound 11. The mixture was purified by flash chromatography
using AcOEt:Hex (1:1). Collection of the pure fractions identified
by LCMS gave 100 mg of pure Compound 11. Calculated mass for
C.sub.27H.sub.30N.sub.2O.sub.7 (M+H).sup.+ 495.1, found by LC-MS
495.2.
Example 10
Preparation of Compound 18 in FIG. 20
[0180] Compound 1 (i.e.,
tert-butyl-1(1S,2R)-2-[(benzyloxy)carbonyl)-3-tert-butoxycarbonyl)-1-meto-
xhycarbonyl)]propylcarbamate) was prepared as described in Example
8 above.
[0181] Preparation of Compound 12 in FIG. 20. Compound 12 is
tert-Butyl-(1S,2R)-2-[(benzylcarboxylate)-3-carboxy)-1-metoxhycarbonyl)]p-
ropylcarbamate. To Compound 1 (13.9 g, 30.8 mmol) was added 45 mL
of a 2M solution of HCl in diethyl ether. The clear yellow solution
was stirred at room temperature for 18 hours. The mixture was
triturated with cold ether which gave a yellow foam. Drying of this
solid gave 8.32 g (84% yield) of the hydrochloride salt
intermediate which was used without further purification in the
next step. This HCl salt crude (8.3 g, 25 mmol) was dissolved in
THF (80 mL). To this clear solution was added TEA (7.6 mL, 2.2 eq)
followed by Boc.sub.2O (6.5 g, 1.2 eq). The mixture was stirred for
18 hours at room temperature. The mixture was then concentrated,
re-dissolved in AcOEt (150 mL), washed with 1N HCl 2.times., sat.
NaCl 1.times., dried over Na.sub.2SO.sub.4, filtered, concentrated
and dried under high vacuum to yield Compound 12 as a brownish oil
(11.1 g, 100% crude yield), which was used without further
purification in the next step. Calculated mass for
C.sub.19H.sub.25NO.sub.8 (M+H).sup.+ 396.1, found by LC-MS
396.2.
[0182] Preparation of Compound 13 in FIG. 20. Compound 13 is
tert-Butyl-(1S,2R)-2-[(benzylcarboxylate)-3-ethylthiocarboxylate)-1-metox-
hycarbonyl)]propylcarbamate. DCC (5.9 g, 1.1 eq) was added to a
solution of crude Compound 12 (10.4 g, 26.2 mmol), EtSH (2.15 mL,
1.1 eq) and 4-dimethylaminopyridine (DMAP) (0.32 g, 0.1 eq)
dissolved in DCM (28 mL). After 6 hours the mixture was
concentrated, re-dissolved in AcOEt (150 mL) washed with 1N HCl
2.times., sat. NaCl 1.times., dried over Na.sub.2SO.sub.4,
filtered, concentrated and dried under high vacuum to yield
Compound 13 as a brown oil (7.6 g), which was used without further
purification in the next step. Calculated mass for
C.sub.21H.sub.29NO.sub.7S (M+H).sup.+ 440.1, found by LC-MS
440.2.
[0183] Preparation of Compound 14 in FIG. 20. Compound 14 is
(1S,2R)-2-[(benzyl-carboxylate)-3-ethylthiocarboxylate)-1-metoxhycarbonyl-
)]propylamine hydrochloride salt. Crude Compound 13 (7.6 g, 17.2
mmol) was dissolved in ethyl ether (8 mL), followed by addition of
a 2N solution of HCl in diethyl ether (40 mL). The clear mixture
was stirred at room temperature for 18 hours. The mixture was
concentrated to give Compound 14 as an orange oil (7.5 g) which was
used without further purification in the next step. Calculated mass
for C.sub.16H.sub.21NO.sub.5S (M+H).sup.+ 338.1, found by LC-MS
338.2.
[0184] Preparation of Compound 15 in FIG. 20. Compound 15 is
(1S,2R)-2-[(benzyl-carboxylate)-3-ethylthiocarboxylate)-1-metoxhycarbonyl-
)]propyl-L-N-Boc-Ala. Crude Compound 14 (6.6 g, 17.7 mmol),
Boc-L-Ala-OH (3.7 g, 1.1 eq) and
2-(7-aza-1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluoride (HATU) (12.1 g, 1.8 eq) were dissolved in ACN (150
mL). To this solution was added DIEA (6.1 mL, 2 eq) and the mixture
was stirred at room temperature for 6 hours. The mixture was
concentrated, re-dissolved in AcOEt (150 mL), washed with sat
NH.sub.4Cl 2.times., sat. NaCl 1.times., dried over
Na.sub.2SO.sub.4, filtered, concentrated and dried under high
vacuum to yield compound 15 as a brown oil (16.5 g of crude).
Purification by flash chromatography using Hex; AcOEt (6:4) gave
pure compound 15 (3.55 g, 40% yield). Calculated mass for
C.sub.24H.sub.34N.sub.2O.sub.8S (M+H).sup.+ 511.1, found by LC-MS
511.2.
[0185] Preparation of Compound 16 in FIG. 20. Compound 16 is
(1S,2R)-2-[(benzyl-carboxylate)-3-formyl)-1-metoxhycarbonyl)]propyl-L-N-B-
oc-Ala. Triethylsilane (5.6 mL, 5 eq) was slowly added, under
argon, to a solution of Compound 15 (3.5 g, 6.9 mmol) and Pd--C
(0.6 g) dissolved in acetone (16 mL) in an ice bath
(.about.4.degree. C.). After addition of TES the reaction was
stirred at 10-20.degree. C. After 4 hours, thin layer
chromatography (TLC) showed complete transformation. The reaction
was filtered and concentrated to give an off-green oil.
Purification by flash chromatography using Hex; AcOEt (6:4) gave
pure Compound 16 (2.9 g, 93% yield). Calculated mass for
C.sub.22H.sub.30N.sub.2O.sub.8 (M+H).sup.+ 452.1, found by LC-MS
452.2.
[0186] Preparation of Compound 17 in FIG. 20. Compound 17 is
(3R,6S,7R)-7-(benzyloxy-carbonyl)-6-amino-(L-Boc-Ala)-hexahydro-5-oxo-2H--
thiazolo[3,2-a]pyridine-3-carboxylic acid. In a high pressure vial
crude Compound 16 (2 g, 4.55 mmol) was dissolved in dry pyridine
(12 mL). To this mixture was added L-Cys-OH (0.88 g, 1.6 eq)
followed by addition of 2.7 g of activated 4.degree. A molecular
sieves (powder). The mixture was stirred vigorously at room
temperature for 4 hours. Dry-pyridine (10 mL) was added to the
mixture, the vial was capped and the mixture stirred at 50.degree.
C. for 4 days. The mixture was then filtered through a bed of
celite and washed with tetrahydrofuran (THF) and MeOH. The mixture
was concentrated to give Compound 17 as yellow foam (1.6 g) which
was used without further purification in the next step. Calculated
mass for C.sub.24H.sub.31N.sub.3O.sub.8S (M+H).sup.+ 522.1, found
by LC-MS 522.2.
[0187] Preparation of Compound 18 in FIG. 20. Compound 18 is
(3R,6S,7R)-7-(benzyloxy-carbonyl)-6-amino-(L-Ala)-hexahydro-5-oxo-2H-thia-
zolo[3,2-a]pyridine-3-carboxylic acid. In a round bottom flask
crude Compound 17 (1.6 g, 3.1 mmol) was dissolved in dioxane (15
mL) followed by addition of 4M HCl. The mixture was stirred at room
temperature and after 3 hours LCMS analysis showed complete
conversion to the free amine. The mixture was concentrated,
dissolved with DCM, MeOH, concentrated again and then dried under
high vacuum to give the hydrochloride salt as a brownish semisolid
(1.5 g) which was used without further purification in the next
step. Calculated mass for C.sub.24H.sub.31N.sub.3O.sub.8S
(M+H).sup.+ 522.1, found by LC-MS 522.2.
[0188] This HCl salt was dissolved in DCM (14 mL) followed by
addition of DIEA (2 mL, 3.5 eq) and FmocOSu (1.2 g, 1.1 eq) in
portions as solid. The mixture was stirred for 3 hours showing
complete transformation by LCMS. The mixture was concentrated,
dissolved in AcOEt (60 mL), washed with 2N HCl 2.times., brine,
dried over Na.sub.2SO.sub.4, filtered and concentrated to give 2.1
g of a brownish oil. Purification by flash chromatography using
Hex; AcOEt (5:95) followed by 100% MeOH gave pure compound 18
(0.821 g, 44% yield). Calculated mass for
C.sub.34H.sub.33N.sub.3O.sub.8S (M+H).sup.+ 644.1, found by LC-MS
644.2.
Example 11
Preparation of Compounds in FIG. 21
[0189] Preparation of compound 16 has been described in Example
10.
[0190] Preparation of Compound 19 in FIG. 21. Compound 19 is
(1S,2R)-[2-(benzylcarboxylate)-3-formyl-4-(tert-butoxy-N-2-methyl
acetyl)-1-(methoxycarbonyl)]butyl-L-N-Boc-Ala. Crude compound 16
(1.01 g, 2.24 mmol) and L-Ala-OtBu. HCl (0.449 g, 1.1 eq) were
dissolved in DMF (4.5 mL) at room temperature. NaBH(OAc).sub.3
(0.95 g, 2 eq) was dissolved separately in DMF (4.5 mL) at room
temperature, the two solutions were mixed and stirred at room
temperature for about 2 hours. The reaction was washed with
saturated NaHCO.sub.3 solution 2.times., water 1.times., sat. NaCl
1.times., dried over Na.sub.2SO.sub.4, filtered, concentrated to
yield 0.92 g of Compound 19 as a colorless oil, which was used
without further purification in the next step. Calculated mass for
C.sub.29H.sub.45N.sub.3O.sub.9 (M+H).sup.+ 579.68, found by LC-MS
579.6.
[0191] Preparation of Compound 20 in FIG. 21. Compound 20 is
(1S,2R)-tert-butyl-[4-(benzylcarboxylate)-3-(N-L-Boc-Ala)-2-oxopiperidine-
)-1-methyl-1-yl]acetate. Crude Compound 19 (0.550 g, 0.95 mmol) was
dissolved in DMF (3 mL), DIEA (0.445 mL, 2 eq) was heated using
microwaves at 140.degree. C. for 20 min. The reaction was checked
and then washed with 0.5M HCl 2.times., water 1.times., sat. NaCl
1.times., dried over Na.sub.2SO.sub.4, filtered, concentrated to
give 0.50 g of Compound 20 as a light brownish oil, which was used
without further purification in the next step. Calculated mass for
C.sub.28H.sub.41N.sub.3O.sub.8 (M+H).sup.+ 547.64, found by LC-MS
547.6.
[0192] Preparation of Compound 21 in FIG. 21. Compound 21 is
(1S,2R)-[4-(benzyl-carboxylate)-3-(N-L-Fmoc-Ala)-2-oxopiperidine)-1-methy-
l-1-yl]acetic acid. Crude Compound 20 (0.501 g, 0.91 mmol) was
dissolved in 5 mL of 20% TFA in DCM and stirred for about an hour
at room temperature. The reaction was concentrated and then dried
under high vacuum to give the corresponding TFA salt as brownish
oil (0.47 g) which was used without further purification in the
next step. Calculated mass for C.sub.19H.sub.25N.sub.3O.sub.6
(M+H).sup.+ 505.64, found by LC-MS 505.6
[0193] This TFA salt (0.47 g, 0.91 mmol) was dissolved in aqueous
10% Na.sub.2CO.sub.3 solution (12 mL) and DMF (4 mL), and cooled
down to 0.degree. C. A solution of FmocOSu (0.472 g, 1.5 eq) in DMF
(8 mL) was added dropwise to the cold aqueous solution. After 5
minutes the ice bath was removed and the reaction was stirred
overnight, quenched by adding 40 mL water followed by washings with
AcOEt. The aqueous layer was acidified using 2N HCl (pH=2) and
washed with AcOEt 3.times., NaCl 1.times., dried over
Na.sub.2SO.sub.4, filtered and concentrated. Purification was done
by washing the crude compound with Hex:AcOEt (6:4) 2.times. at room
temperature to give Compound 21 as light colored oil (0.290 g, 52%
yield). Calculated mass for C.sub.34H.sub.35N.sub.3O.sub.8
(M+H).sup.+ 613.24, found by LC-MS 613.2.
[0194] Preparation of Compound 22 in FIG. 21. Compound 22 is
(1S,2R)-[2-(benzylcarboxylate)-3-(formyl)-4-(tert-butoxy-N-acetyl)-1-(met-
hoxycarbonyl)]butyl-L-N-Boc-Ala. Crude compound 16 (1.01 g, 2.24
mmol) and AcOH. NH.sub.2-Gly-OtBu (0.478 g, 1.1 eq) were dissolved
in dry DMF (4.5 mL) at room temperature. NaBH(OAc).sub.3 (0.95 g, 2
eq) was dissolved separately in dry DMF (4.5 mL) at room
temperature, the two solutions were mixed and stirred at room
temperature for about 2 hours. The reaction was washed with
saturated NaHCO.sub.3 solution 2.times., water 1.times., sat. NaCl
1.times., dried over Na.sub.2SO.sub.4, filtered and concentrated to
yield 1.09 g of Compound 22 as a colorless oil, which was used
without further purification in the next step. Calculated mass for
C.sub.28H.sub.43N.sub.3O.sub.9 (M+H).sup.+ 565.68, found by LC-MS
565.3.
[0195] Preparation of Compound 23 in FIG. 21. Compound 23 is
(1S,2R)-tert-butyl-[4-(benzylcarboxylate)-3-(N-L-Boc-Ala)-2-oxopiperidine-
)-1-yl]acetate. Crude compound 22 (0.550 g, 0.95 mmol) was
dissolved in DMF (3 mL), DIEA (0.445 mL, 2 eq) and then heated
using microwaves at 140.degree. C. for 20 min (Biotage.TM.,
Initiator8). The reaction was checked by LCMS. The reaction crude
was washed with 0.5M HCl 2.times., water 1.times., sat. NaCl
1.times., dried over Na.sub.2SO.sub.4, filtered and concentrated to
yield 0.41 g of Compound 23 as a light brownish oil, which was used
without further purification in the next step. Calculated mass for
C.sub.27H.sub.39N.sub.3O.sub.8 (M+H).sup.+ 533.64, found by LC-MS
533.6.
[0196] Preparation of Compound 24 in FIG. 21. Compound 24 is
(1S,2R)-[4-(benzylcarboxylate)-3-(N-L-Fmoc-Ala)-2-oxopiperidine)-1-yl]ace-
tic acid. Crude Compound 23 (0.41 g, 0.76 mmol) was dissolved in 5
mL of 20% TFA in DCM; reaction was stirred for about an hour at
room temperature. The reaction was concentrated and then dried
under high vacuum to give the corresponding TFA salt as a brownish
oil (0.45 g) which was used without further purification in the
next step. Calculated mass for C.sub.18H.sub.23N.sub.3O.sub.6
(M+H).sup.+ 491.3, found by LC-MS 491.4
[0197] This TFA salt (0.45 g, 0.92 mmol) was dissolved in aqueous
10% Na.sub.2CO.sub.3 solution (12 mL) and DMF (4 mL), and cooled
down to 0.degree. C. A solution of FmocOSu (0.472 g, 1.5 eq) in DMF
(8 mL) was added dropwise to the cold aqueous solution. After 5
min, the ice bath was removed and the reaction was stirred
overnight, then quenched by adding about 40 mL water, followed by
washings with AcOEt. The aqueous layer was acidified using 2N HCl
(pH=2) and washed with AcOEt 3.times., NaCl 1.times., dried over
Na.sub.2SO.sub.4, filtered, concentrated. Purification was done by
washing the crude compound with Hex:AcOEt (6:4) 2.times. at room
temperature giving Compound 24 as light colored oil (0.15 g, 27%
yield). Calculated mass for C.sub.33H.sub.33N.sub.3O.sub.8
(M+H).sup.+ 599.6, found by LC-MS 599.4.
Example 12
Preparation of Compounds in FIGS. 1A, 2A, and 5A
[0198] The compound in FIG. 1A may be prepared following the
methods described, e.g., in U.S. Pat. No. 6,872,700, the disclosure
of which is incorporated by reference. The compounds in FIGS. 2A
and 5A may be prepared following the methods described, e.g., in WO
2007/139941, the disclosure of which is incorporated by
reference.
Example 13
Preparation of Compounds in FIGS. 1B-C, 2B-U, 3A-G, 5B-G, 6A-E,
10A-I, 11A-C, 12, 13A-B, 14B-C, 14E-R
[0199] For each compound in FIGS. 1B, 1C, 2B, 2C, 2D, 2E, 2F, 2G,
2H, 2I, 2J, 2K, 3A, 3B, 3C, 3D, 3E, 3F, 3G, 5B, 5C, 5D, 6A, 6B, 6C,
6D, and 6E, a calculated 100 .mu.mol of Fmoc-Ser(OtBu)-Wang resin
or Fmoc Rink amide resin was weighed into a reaction vessel in a
Symphony peptide synthesizer, and peptide elongation was carried
out following standard Fmoc peptide synthesis protocol. If an
unnatural amino acid was used at position 2 this was incorporated
manually in a polypropylene syringe. Cleavage of the peptide from
the resin was done with 10 mL TFA/H.sub.2O/PhOH/TIPS (95:2:2:1),
then precipitated by methyl-tert-Butyl ether. The crude was
dissolved and applied to a reverse-phase HPLC column (C.sub.18,
20-50% CH.sub.3CN in 0.1% TFA/H.sub.2O over 30 min gradient) to
afford the titled compounds as white powders. All characterized by
LC-MS. The compounds in FIGS. 2L-U, 5E-G, 10A-I, 13B, 14B-C and
14E-K will be prepared following the methods described in this
example.
[0200] With respect to the compounds in FIGS. 14L-R, a calculated
100 .mu.mol of Fmoc-Rink-amide resin was weighed into a reaction
vessel in a Symphony peptide synthesizer, and peptide elongation
was carried out following standard Fmoc peptide synthesis protocol.
If an unnatural amino acid was used at position 2 this was
incorporated manually in a polypropylene syringe. Only for the
compounds in FIGS. 14N-O, this procedure was carried out under the
following microwave-assisted conditions: A microwave vial was
loaded with the corresponding peptide-resin intermediate (0.3 g,
0.14 mmol), Fmoc-AA-OH (4 eq), PyBrop (0.32 g, 4.8 eq),
2,6-lutidine (0.25 mL, 15 eq), dichloroethane (DCE) (2-3 mL) and
DMF (about 0.3 mL). The vial was capped and heated with microwaves
(Biotage.TM., Initiator8) at 100.degree. C. for 11 min. The resin
was filtered, washed with DCE and MeOH. Cleavage of the peptide
from the resin was done with 10 mL TFA/H.sub.2O/PhOH/TIPS
(95:2:2:1), then precipitated by methyl-tert-Butyl ether. The crude
was dissolved and applied to a reverse-phase HPLC column (C.sub.18,
20-50% CH.sub.3CN in 0.1% TFA/H.sub.2O over 30 min gradient) to
afford the titled compounds as white powders. All characterized by
LC-MS.
Example 14
Preparation of Compounds in FIGS. 8A-H
[0201] For the compounds in FIGS. 8B, 8C, 8D, 8E, 8F, 8G, and 8H, a
calculated 100 mol of Fmoc-Ser(OtBu)-Wang or Fmoc-Rink-amide resin
was weighed into a reaction vessel in a Symphony peptide
synthesizer, and the peptide elongation was carried out following
standard Fmoc peptide synthesis protocol. The corresponding L- or
D-Cys(Trt)-OH was introduced at positions 2 and 4. Cleavage of the
peptide from the resin with 10 mL TFA/H.sub.2O/PhOH/TIPS (95:2:2:1)
then precipitated by methyl-tert-Butyl ether. The crude peptides
were dried overnight under high vacuum.
[0202] Disulfide cylclization: Clear-OX resin (0.39 g, 3.times.
molar excess) was swollen on DCM for 45 min at room temperature,
then washed with DCM 2.times., DMF 3.times., MeOH 3.times.,
deionized water 3.times. and finally H.sub.2O:ACN (1:1) 3.times..
The corresponding crude peptide (0.1 g) was dissolved in degassed
1:1 v/v solution of 0.1M NH.sub.4OAc buffer (pH=6.5)/ACN. The
peptide solution was then added to the pre-swollen Clear-OX resin
and the slurry was shacked at room temperature. After 2-3 hours the
cyclization was complete. The resin was washed with a small amount
of ACN/H.sub.2O (1:1) solution, the filtrate concentrated to remove
volatiles and then lyophilized. The crude was dissolved and applied
to a reverse-phase HPLC column (C.sub.18, 20-50% CH.sub.3CN in 0.1%
TFA/H.sub.2O over 30 min gradient) to afford the titled compounds
as white powders. All characterized by LC-MS. The compound in FIG.
8A will be prepared following the methods described in this
example.
Example 15
Preparation of Compounds in FIGS. 9A-H
[0203] For each compound in FIGS. 9A, 9B, 9C, 9D, 9E, 9G, and 9H, a
calculated 100 .mu.mol of Fmoc-Rink amide resin was weighed into a
reaction vessel in a Symphony peptide synthesizer, and the peptide
elongation was carried out following standard Fmoc peptide
synthesis protocol. The amino acid at position 2 of all these
compounds was introduced by special coupling conditions. A
microwave vial was loaded with the corresponding peptide-resin
intermediate (0.3 g, 0.14 mmol), Fmoc-AA-OH (4 eq), PyBrop (0.32 g,
4.8 eq), 2,6-lutidine (0.25 mL, 15 eq), dichloroethane (DCE) (2-3
mL) and DMF (-0.3 mL). The vial was capped and heated with
microwaves (Biotage.TM., Initiator8) at 100.degree. C. for 11 min.
The resin was filtered, washed with DCE and MeOH. For some
compounds the above process was repeated twice. The resin is then
treated in a cycle of deprotection, coupling with Fmoc-His(Trt)-OH,
HBTU and HOBt, deprotection. Cleavage of the peptide from the resin
was done with 10 mL TFA/H.sub.2O/PhOH/TIPS (95:2:2:1), then
precipitated by methyl-tert-Butyl ether. The crude was dissolved
and applied to a reverse-phase HPLC column (C.sub.18, 20-50%
CH.sub.3CN in 0.1% TFA/H.sub.2O over 30 min gradient) to afford the
titled compounds as white powders. All characterized by LC-MS. The
compound in FIG. 9F will be prepared following the methods
described in this example.
Example 16
In Vitro Assay
[0204] The compounds shown in Table 1 below were analyzed in an in
vitro functional assay at the GLP-1 receptor. The assay was
conducted as follows: Membrane fractions were prepared from
confluent cultures of RIN m5f cells. Compounds were serially
diluted with an assay buffer, and then added to a 96-well assay
plate containing RIN m5f cell membranes in an ATP/GTP mixture.
Cyclase activities were determined by measuring the production of
cAMP induced through GLP-1 receptor activation. Quantification of
cAMP production was achieved through a competitive
chemiluminescence assay with a biotinylated-cAMP probe using Perkin
Elmer Fusion.TM.-Alpha Microplate Analyzer (AlphaScreen.TM.
technology). The compound EC.sub.50 values were obtained through
fitting the concentration-response curves to a four-parameter
logistic equation within GraphPad PRISM.RTM. software. The results
of the assay are presented in Table 1 below.
Example 17
In Vivo Assay
[0205] Some compounds shown in Table 1 below were analyzed in an in
vivo basal glucose lowering assay using the following procedure: A
subcutaneous injection of either 200 .mu.l phosphate-buffered
saline (PBS) vehicle or test article was given immediately
following baseline glucose (t=0) to NIH/Swiss female mice. Tail
blood glucose samples were measured at t=2 and 4 hours post dose
using a OneTouch.RTM. Ultra.RTM. (LifeScan, Inc., a Johnson &
Johnson Company, Milpitas, Calif.). Body weight was measured daily.
Significant test sample effects were identified by ANOVA
(p<0.05), followed by Dunnett's post test using GraphPad Prism
version 4.00 for Windows (GraphPad Software, San Diego Calif.). The
results are presented in Table 1 below.
TABLE-US-00004 TABLE 1 Compound in Cyclase GLP-1 Receptor In Vivo
FIG. EC.sub.50 (nM) Glucose-Lowering Assay 1A 0.01 not tested 1B
0.004 not tested 1C 0.029 not tested 2A 0.008 greater than 3 hours
2B 0.0089 more than 4 hours 2C 6 not tested 2D 0.04 not tested 2E
2.15 not tested 2F 0.027 more than 4 hours 2G 0.89 not tested 2H
0.124 not tested 2I 0.054 more than 4 hours 2J 7.2 not tested 2K
0.29 similar to GLP-1 3A 0.007 more than 4 hours 3B 0.007 more than
2 hours 3C 0.022 not tested 3D 1.03 not tested 3E 0.06 more than 2
hours 3F 1.089 not tested 3G 0.065 similar to GLP-1 5A 1.83 more
than 4 hours 5B 0.53 more than 4 hours 5C 1.056 not tested 5D 10.5
not tested 6A 0.144 similar to GLP-1 6B 0.52 not tested 6C 151.9
not tested 6D 0.282 not tested 6E 0.60 more than 4 hours 8B 1.26
similar to GLP-1 8C 968.6 not tested 8D 106.2 not tested 9A 0.21
not tested 9B 0.03 more than 4 hours 9C 0.05 more than 4 hours 9D
0.01 more than 4 hours 9E 133 not tested 9F 0.07 more than 4 hours
9G 1.9 not tested 9H 0.1 not tested 11A 0.155 not tested 11B 0.007
not tested 11C 0.011 not tested 12 0.028 not tested 13 0.274 not
tested 14J 0.054 not tested 14K 3.5 not tested 14L 0.05 not tested
14M 0.2 (partial agonist) not tested 14N 0.004 not tested 14O 0.24
not tested 14P 0.25 not tested 14Q 0.02 not tested 14R 0.41
(partial agonist) not tested 15A 0.57 inactive 15B 1000 not tested
15C 2.46 inactive 15D 1.7 inactive 16A 0.52 inactive 16B 0.18
similar to GLP-1 16C 1.1 inactive 16D 1 inactive 16E 1 inactive 16F
0.61 about 30 minutes 16G 56 not tested 16H 1000 not tested 17A 105
not tested 17B 668 not tested 17C 10,000 not tested
Example 18
Preparation of Compounds in FIGS. 17A-F
[0206] A calculated 100 .mu.mol of Rink amide resin was weighed
into a reaction vessel in a Symphony peptide synthesizer, and the
peptide elongation was carried out following standard Fmoc peptide
synthesis protocol up to residue Pro.sup.3. The resulting
peptide-resin intermediate (0.3 g, 0.0927 mmol) was swollen in DCM
with around 5% DMF and to the slurry was added Fmoc-Cys(Trt)-OH
(0.351 g, 4 eq), followed by Bromo-tris-pyrrolidino-phosphonium
hexafluorophosphate (PyBrop) (0.34 g, 4.8 eq) and 2,6-lutidine
(0.27 mL, 15 eq). The vial was capped and heated in a microwave
apparatus (Biotage Initiator8) at 100.degree. C. for 11 min. The
resin was filtered and washed with DMF 6.times., treated with 20%
piperidine in DMF 2.times.25 min and washed with DMF 6.times., DCM
4.times. followed by treatment with 2% TFA/1.5% TIS in DCM
4.times.10 min. then washed with DCM 4.times., DMF 2.times. and
TMOF 3.times.. In a polypropylene syringe the resin is swollen in
TMOF, followed by addition of compound 25 (0.2 g, 3 eq) and dry
pyridine (0.06 mL, 5 eq). The resin was shaken at room temperature
for 16 hours, followed by washings with TMOF 3.times., DCM
3.times., MeOH 3.times. and dried under high vacuum. Cleavage of
the peptide from the resin was carried out with 10 ml
TFA/H.sub.2O/PhOH/TIPS (95:2:2:1) (TFA is trifluoroacetic acid;
TIPS is triisopropylsilyl), precipitated by methyl-tert-Butyl
ether. The residue was dissolved in 0.8 ml of MeOH and 0.8 ml of
ACN. To this solution 0.1 ml of DEA were added and the mixture
stirred at room temperature overnight. The resulting residue was
applied to a reverse-phase high performance liquid chromatography
(HPLC) column (C.sub.18, 20-50% CH.sub.3CN in 0.1% TFA/H.sub.2O
over 30 min gradient) to afford compound 17A as a white powder (5.3
mg, 3%): Retention time in reverse phase-high performance liquid
chromatography (RP-HPLC) (C.sub.18, 5-75% CH.sub.3CN in 0.1%
TFA/H.sub.2O over 15 min) is 8.71 min; Calculated mass for
C.sub.146H.sub.228N.sub.38O.sub.43S (M+H).sup.+ 3235.74, found by
liquid chromatography/mass spectrometry (LC-MS) 1079.6
(M+3H).sup.3+, 1619.9 (M+2H).sup.2+.
[0207] The synthesis of compounds 17B and 17C was performed similar
as reported above for compound 17A, with the difference of using
Fmoc-D-Cys(Trt)-OH and Fmoc-Pen-OH, respectively. After
purification compound 17B was obtained as a white powder (8 mg,
7%): Retention time in reverse phase-high performance liquid
chromatography (RP-HPLC) (C.sub.18, 5-75% CH.sub.3CN in 0.1%
TFA/H.sub.2O over 15 min) is 8.55 min; Calculated mass for
C.sub.146H.sub.228N.sub.38O.sub.43S (M+H).sup.+ 3235.74, found by
liquid chromatography/mass spectrometry (LC-MS) 1079.6
(M+3H).sup.3.alpha., 1619.9 (M+2H).sup.2+. After purification
compound 17C was obtained as a white powder (1.5 mg, 3%): Retention
time in reverse phase-high performance liquid chromatography
(RP-HPLC) (C.sub.18, 5-75% CH.sub.3CN in 0.1% TFA/H.sub.2O over 15
min) is 8.55 min; Calculated mass for
C.sub.148H.sub.232N.sub.38O.sub.43S (M+H).sup.+ 3263.79, found by
liquid chromatography/mass spectrometry (LC-MS) 1089.6
(M+3H).sup.3+, 1632.9 (M+2H).sup.2+.
Example 19
Preparation of Compound 25
[0208] In a round bottom flask Fmoc-His(Boc)-OH (4 g, 1 eq) was
dissolved in DCM (50 mL). To this solution was added DCC (1.9 g,
1.1 eq), EtSH (0.7 mL, 1.1 eq) and DMAP (0.102 g, 0.1 eq). The
mixture was stirred at room temperature for 6 h. The reaction
mixture was filtered and the solution concentrated to yield 4.9 g
of an off-white solid. The crude product was purified by flash
chromatography using Hex:AcOEt (1:1). After concentration of the
pure fractions the corresponding thioester was obtained as a clear
oil (3.6 g, 84%). The thioester (0.69 g, 1 eq) was dissolved in THF
(11 mL) and stirred under Argon atmosphere for few minutes. To this
solution was added Pd--C (0.180 g) and the mixture stirred under
Argon for 10 min followed by dropwise addition of TES (0.75 mL, 3.5
eq) and the mixture stirred at room temperature. After 4 h one more
equivalent of TES was added, one hour later the crude mixture was
filtered through a bed of silica/celite and washed with THF. The
filtrate was concentrated to give a dark brown oil, which was
purified by flash chromatography in a short (20 mL) silica gel
column using Hex:AcOEt (2:8). After concentration of the pure
fractions compound 25 was obtained as a clear semisolid (0.26 g,
50%).
Example 20
Modified Exendin Peptides
[0209] N-Terminus conformationally constrained GLP-1 receptor
agonist compounds described herein were covalently linked to one or
more polyethylene glycol and/or fatty acids, as described herein.
In particular, the following twelve compounds 23A-L were
prepared:
[0210] Compound 23A:
4-imidazopropionyl-dAla-PGTFTSDLSK.sup.12QMEEEAVRLFIE-WLKNGGPSSGAPPPS-NH.-
sub.2, wherein K.sup.12 was modified with
--C(.dbd.O)--CH.sub.2(OCH.sub.2CH.sub.2).sub.2NH--C(.dbd.O)CH.sub.2--(OCH-
.sub.2CH.sub.2).sub.2NH--C(.dbd.O)--(CH.sub.2).sub.6--CH.sub.3 (SEQ
ID NO:105).
[0211] Compound 23B:
4-imidazopropionyl-dAla-PGTFTSDLSK.sup.12QMEEEAVRLFIE-WLKNGGPSSGAPPPS-NH.-
sub.2, wherein K.sup.12 was modified with
--C(.dbd.O)--CH.sub.2(OCH.sub.2CH.sub.2).sub.2NH--C(.dbd.O)CH.sub.2(OCH.s-
ub.2CH.sub.2).sub.2NH--C(.dbd.O)--CH(NH.sub.2)--(CH.sub.2).sub.7--CH.sub.3-
(SEQ ID NO:106).
[0212] Compound 23C:
4-imidazopropionyl-dAla-PGTFTSDLSK.sup.12QMEEEAVRLFIE-WLKNGGPSSGAPPPS-NH.-
sub.2, wherein K.sup.12 was modified with
--C(.dbd.O)--CH.sub.2(OCH.sub.2CH.sub.2).sub.2NH--C(.dbd.O)CH.sub.2(OCH.s-
ub.2CH.sub.2).sub.2NH--C(.dbd.O)--CH[NH--C(.dbd.O)(CH.sub.2).sub.6CH.sub.3-
]-(CH.sub.2).sub.7--CH.sub.3(SEQ ID NO:107).
[0213] Compound 23D:
4-imidazopropionyl-dAla-PGTFTSDLSK.sup.12QMEEEAVRLFIE-WLKNGGPSSGAPPPS-NH.-
sub.2, wherein K.sup.12 was modified with
--C(.dbd.O)--CH.sub.2(OCH.sub.2CH.sub.2).sub.2NH--C(.dbd.O)CH.sub.2(OCH.s-
ub.2CH.sub.2).sub.2NH--C(.dbd.O)--CH.sub.2CH.sub.2--CH[C(OH)(.dbd.O)]--NH--
-C(.dbd.O)--(CH.sub.2).sub.16-[C(OH)(.dbd.O)] (SEQ ID NO:108).
[0214] Compound 23E:
4-imidazopropionyl-dAla-PGTFTSDLSKQMEEEAVRLFIEW-LK.sup.27NGGPSSGAPPPS-NH.-
sub.2, wherein K.sup.27 was modified with
--C(.dbd.O)--CH.sub.2(OCH.sub.2CH.sub.2).sub.2NH--C(.dbd.O)CH.sub.2(OCH.s-
ub.2CH.sub.2).sub.2NH--C(.dbd.O)--(CH.sub.2).sub.6--CH.sub.3 (SEQ
ID NO:109).
[0215] Compound 23F:
4-imidazopropionyl-dAla-PGTFTSDLSKQMEEEAVRLFIEW-LK.sup.27NGGPSSGAPPPS-NH.-
sub.2, wherein K.sup.27 was modified with
--C(.dbd.O)--CH.sub.2(OCH.sub.2CH.sub.2).sub.2NH--C(.dbd.O)CH.sub.2(OCH.s-
ub.2CH.sub.2).sub.2NH--C(.dbd.O)--CH(NH.sub.2)--(CH.sub.2).sub.7--CH.sub.3
(SEQ ID NO:110).
[0216] Compound 23G:
4-imidazopropionyl-dAla-PGTFTSDLSKQMEEEAVRLFIEW-LK.sup.27NGGPSSGAPPPS-NH.-
sub.2, wherein K.sup.27 was modified with
--C(.dbd.O)--CH.sub.2(OCH.sub.2CH.sub.2).sub.2NH--C(.dbd.O)CH.sub.2(OCH.s-
ub.2CH.sub.2).sub.2NH--C(.dbd.O)--CH[NH--C(.dbd.O)(CH.sub.2).sub.6CH.sub.3-
]-(CH.sub.2).sub.7--CH.sub.3 (SEQ ID NO:111).
[0217] Compound 23H:
4-imidazopropionyl-dAla-PGTFTSDLSKQMEEEAVRLFIEW-LK.sup.27NGGPSSGAPPPS-NH.-
sub.2, wherein K.sup.27 was modified with
--C(.dbd.O)--CH.sub.2(OCH.sub.2CH.sub.2).sub.2NH--C(.dbd.O)CH.sub.2(OCH.s-
ub.2CH.sub.2).sub.2NH--C(.dbd.O)--CH.sub.2CH.sub.2--CH[C(OH)(.dbd.O)]--NH--
-C(.dbd.O)--(CH.sub.2).sub.16-[C(OH)(.dbd.O)](SEQ ID NO:112).
[0218] Compound 23I:
4-imidazopropionyl-dAla-PGTFTSDLSKQMEEEAVRLFIEWLKN-GGPSSGAPPPS.sup.39,
wherein S.sup.39 was modified with
-Lys(NH.sub.2)--C(.dbd.O)--CH.sub.2(OCH.sub.2CH.sub.2).sub.2NH--C(.dbd.O)-
CH.sub.2(OCH.sub.2CH.sub.2).sub.2NH--C(.dbd.O)--(CH.sub.2).sub.6--CH.sub.3
(SEQ ID NO:113).
[0219] Compound 23J:
4-imidazopropionyl-dAla-PGTFTSDLSKQMEEEAVRLFIEWLKN-GGPSSGAPPPS.sup.39,
wherein S.sup.39 was modified with
-Lys(NH.sub.2)--C(.dbd.O)--CH.sub.2(OCH.sub.2CH.sub.2).sub.2NH--C(.dbd.O)-
CH.sub.2(OCH.sub.2CH.sub.2).sub.2NH--C(.dbd.O)--CH(NH.sub.2)--(CH.sub.2).s-
ub.7--CH.sub.3 (SEQ ID NO:114).
[0220] Compound 23K:
4-imidazopropionyl-dAla-PGTFTSDLSKQMEEEAVRLFIEWLKN-GGPSSGAPPPS.sup.39,
wherein S.sup.39 was modified with
-Lys(NH.sub.2)--C(.dbd.O)--CH.sub.2(OCH.sub.2CH.sub.2).sub.2NH--C(.dbd.O)-
CH.sub.2(OCH.sub.2CH.sub.2).sub.2NH--C(.dbd.O)--CH[NH--C(.dbd.O)(CH.sub.2)-
.sub.6CH.sub.3]-(CH.sub.2).sub.7--CH.sub.3 (SEQ ID NO:115).
[0221] Compound 23L:
4-imidazopropionyl-dAla-PGTFTSDLSKQMEEEAVRLFIEWLKN-GGPSSGAPPPS.sup.39,
wherein S.sup.39 was modified with
--C(.dbd.O)--CH.sub.2(OCH.sub.2CH.sub.2).sub.2NH--C(.dbd.O)CH.sub.2(OCH.s-
ub.2CH.sub.2).sub.2NH--C(.dbd.O)--CH.sub.2CH.sub.2--CH[C(OH)(.dbd.O)]--NH--
-C(.dbd.O)--(CH.sub.2).sub.16-[C(OH)(.dbd.O)] (SEQ ID NO:116).
[0222] For each of Compound Nos. 23A-L above, a calculated 100
.mu.mol of Fmoc-Rink-amide resin was weighed into a reaction vessel
in a Symphony peptide synthesizer, and peptide elongation was
carried out following standard Fmoc peptide synthesis protocol. The
dAla at position 2 was incorporated manually in a polypropylene
syringe. The orthogonal protection (alloc group) of the side chain
group (Lys.sup.12, Lys.sup.27 or Lys.sup.40) was performed as
follows: The peptide-resin was swollen in DCM and dimethylamino
borane-complex (6 eq) followed after about 3 minutes by
tetrakis(triphenylphosphine)palladium(0) (0.1 eq). The resin was
shaken for 15 minutes, washed with DCM 3.times. and the process
repeated. Then, the resin was washed with DCM 3.times., 10% DIEA in
DCM 2.times., DCM 3.times. and MeOH 2.times.. At this point, the
peptide-resin gave a positive chloranil test. The resulting
peptide-resin intermediate (0.3 g, 0.0927 mmol) was swollen in DMF
and to the slurry was added the corresponding polyethylene glycol
(2.2 eq), followed by HBTU (0.035 g, 2.2 eq), HOBt (0.03 g, 2.2 eq)
and NMM (0.04 mL, 4.4 eq). After 3 hours, the resin was washed with
DMF 6.times., treated with 20% piperidine in DMF 2.times.25 min and
washed with DMF 6.times.. The above cycle was repeated with a
second Fmoc-(polyethylene glycol)-OH in most cases. The coupling of
the corresponding fatty acid chain was done using two different
microwave-assisted methods: the corresponding acyl chloride (5 eq)
and NMM (7 eq) were added to the resin swollen in a 1:1 DMF:DCM
mixture, and then heated using microwaves at 75.degree. C. for 20
min (Biotage.TM., Initiator8); or the corresponding carboxylic or
dicarboxylic acid (5 eq), HOAt (5 eq) and DIC (5 eq) were added to
the slurry resin on DMF, and then heated using microwaves at
75.degree. C. for 15 min (Biotage.TM., Initiator8). Cleavage of the
peptide from the resin was done with 10 mL TFA/H.sub.2O/PhOH/TIPS
(95:2:2:1), then precipitated by methyl-tert-Butyl ether. The crude
was dissolved and applied to a reverse-phase HPLC column (C.sub.18,
20-50% CH.sub.3CN in 0.1% TFA/H.sub.2O over 30 min gradient) to
afford the titled compounds as white powders. All were
characterized by LC-MS.
[0223] Each of these compounds was analyzed in an in vitro
functional assay at the GLP-1 receptor following the methods
described in Example 16. The results are in Table 2:
TABLE-US-00005 TABLE 2 Cyclase GLP-1 Receptor Compound EC.sub.50
(nM) 23A 0.027 23B 0.027 23C 0.06 23D 0.22 23E 0.3 23F 0.1 23G 0.7
23H 0.08 23I 0.01 23J 0.01 23K 0.02 23L 0.185
Example 21
Modified Exendin Peptides
[0224] N-Terminus conformationally constrained GLP-1 receptor
agonist compounds described herein were covalently linked to one or
more biotin, as described herein. In particular, the following
compounds 24A-L were prepared:
TABLE-US-00006 Compound 24A: (SEQ ID NO: 1117)
His-dAla-PGTFTSDLSKQMEEEAVRLFIEWL-Lys(biotin)-
NGGPSSGAPPS-Lys[(NH.sub.2)(biotin)]. Compound 24B: (SEQ ID NO: 69)
4-imidazopropionyl-GEGTFTSDLSKQMEEEAVRLFIEWL-
Lys(biotin)-NGGPSSGAPPS-Lys[(NH.sub.2)(biotin)]. Compound 24C: (SEQ
ID NO: 70) 4-imidazopropionyl-GEGTFTSDLSKQMEEEAVRLFIEWLKN-
Lys[(NH.sub.2)(biotin)]. Compound 24D: (SEQ ID NO: 71)
4-imidazopropionyl-APGTFTSDLSKQMEEEAVRLFIEWLKN-
Lys[(NH.sub.2)(biotin)]. Compound 24E: (SEQ ID NO: 118)
His-dAla-PGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-
Lys(NH2)-(O-CH.sub.2-CH.sub.2).sub.2-KAKAEAEAKAKAEAEA-biotin.
Compound 24F: (SEQ ID NO: 119)
His-dAla-PGTFTSDLSKQMEEEAVRLFIEWLE[-(O-CH.sub.2-CH.sub.2).sub.2-
(biotin)]-NGGPSSGAPPPS-NH.sub.2. Compound 24G: (SEQ ID NO: 120)
His-dAla-PGTFTSDLSEK[-(O-CH.sub.2-CH.sub.2).sub.2-(biotin)]-
QMEEEAVRLFIEWLKNGGPSSGAPPPS-NH.sub.2.
[0225] For each of Compound Nos. 24A-G above, a calculated 100
.mu.mol of Fmoc-Rink-amide resin was weighed into a reaction vessel
in a Symphony peptide synthesizer, and peptide elongation was
carried out following standard Fmoc peptide synthesis protocol. If
an unnatural amino acid was used at position 2 this was
incorporated manually in a polypropylene syringe. The orthogonal
protection (alloc group) of the side chain group (Lys.sup.27,
Lys.sup.28 or Lys.sup.40) was performed as follows: The
peptide-resin was swollen in DCM and dimethylamino borane-complex
(6 eq) followed after about 3 minutes by
tetrakis(triphenylphosphine)palladium(0) (0.1 eq). The resin was
shaken for 15 min, washed with DCM 3.times. and the process
repeated. Then, the resin was washed with DCM 3.times., 10% DIEA in
DCM 2.times., DCM 3.times. and MeOH 2.times.. At this point, the
peptide-resin gave a positive chloranil test. The biotin moiety
(one or two) was coupled to the free amino group using the standard
solid-phase coupling conditions described above (HBTU, HOBt, NMM).
Cleavage of the peptide from the resin was done with 10 mL
TFA/H.sub.2O/PhOH/TIPS (95:2:2:1), then precipitated by
methyl-tert-Butyl ether. The crude was dissolved and applied to a
reverse-phase HPLC column (C.sub.18, 20-50% CH.sub.3CN in 0.1%
TFA/H.sub.2O over 30 min gradient) to afford the titled compounds
as white powders. All were characterized by LC-MS.
[0226] Each of these compounds was analyzed in an in vitro
functional assay at the GLP-1 receptor following the methods
described in Example 16. The results are in Table 3:
TABLE-US-00007 TABLE 3 Cyclase GLP-1 Receptor Compound EC.sub.50
(nM) 24A 0.04 24B 0.03 24C 0.07 24D 0.77 24E 0.06 24F 0.06 24G
0.01
Example 22
Compounds of FIG. 10
[0227] With respect to FIG. 10, the following compounds 10J-10N
were made:
TABLE-US-00008 10J: (SEQ ID NO: 72)
4-imidazopropionyl-GPGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPPS-NH.sub.2
10K: (SEQ ID NO: 121)
4-imidazopropionyl-dAla-PGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPPS-NH.sub.2.
10L: (SEQ ID NO: 73)
4-imidazopropionyl-Aib-PGTFTSDLSKQLEEEAVRLFIEWLKNGGPSSGAPPPS-NH.sub.2
10M: (SEQ ID NO: 74)
4-imidazopropionyl-GEGTFTSDLSKQLEEEAVRLFIEWLKQGGPSKEIIS-OH 10N:
(SEQ ID NO: 122)
4-imidazopropionyl-dAla-PGTFTSDLSKQLEEEAVRLFIEWLKQGGPSKEIIS-OH.
[0228] For each of Compounds 10J-N, a calculated 100 .mu.mol of
Fmoc-Rink-amide resin was weighed into a reaction vessel in a
Symphony peptide synthesizer, and peptide elongation was carried
out following standard Fmoc peptide synthesis protocol. If an
unnatural amino acid was used at position 2 this was incorporated
manually in a polypropylene syringe. Only for the compound in FIG.
10L, this procedure was carried out under the following
microwave-assisted conditions: a microwave vial was loaded with the
corresponding peptide-resin intermediate (0.3 g, 0.14 mmol),
Fmoc-AA-OH (4 eq), PyBrop (0.32 g, 4.8 eq), 2,6-lutidine (0.25 mL,
15 eq), dichloroethane (DCE) (2-3 mL) and DMF (.about.0.3 mL). The
vial was capped and heated with microwaves (Biotage.TM.,
Initiator8) at 100.degree. C. for 11 min. The resin was filtered,
washed with DCE and MeOH. Cleavage of the peptides from the resins
was done with 10 mL TFA/H.sub.2O/PhOH/TIPS (95:2:2:1), then
precipitated by methyl-tert-Butyl ether. The crude was dissolved
and applied to a reverse-phase HPLC column (C.sub.18, 20-50%
CH.sub.3CN in 0.1% TFA/H.sub.2O over 30 min gradient) to afford the
titled compounds as white powders. All characterized by LC-MS.
[0229] Compounds 10J-L were analyzed in an in vitro functional
assay at the GLP-1 receptor following the methods described in
Example 16. The results are in Table 4:
TABLE-US-00009 TABLE 4 Cyclase GLP-1 Receptor Compound EC.sub.50
(nM) 10J 0.1 10K 0.03 10L 0.005 10M 0.007 10N 0.01
[0230] All publications and patent applications are incorporated
herein by reference. Although the foregoing has been described in
detail for purposes of clarity of understanding, it will be
apparent to one of ordinary skill in the art that changes and
modifications may be made without departing from the spirit or
scope of the disclosure or appended claims.
Sequence CWU 1
1
122128PRTArtificial SequenceFormula (B); Description of Artificial
Sequence Synthetic polypeptide 1Xaa Xaa Xaa Xaa Thr Phe Thr Ser Asp
Leu Ser Lys Gln Xaa Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile
Glu Xaa Leu Lys Asn 20 25 228PRTArtificial SequenceFormula (C);
Description of Artificial Sequence Synthetic polypeptide 2Xaa Xaa
Xaa Xaa Thr Phe Thr Ser Asp Leu Ser Lys Gln Xaa Glu Glu 1 5 10 15
Glu Ala Val Arg Leu Phe Ile Glu Xaa Leu Lys Xaa 20 25
339PRTArtificial SequenceFormula (D); Description of Artificial
Sequence Synthetic polypeptide 3Xaa Xaa Xaa Xaa Thr Phe Thr Ser Asp
Leu Ser Lys Gln Xaa Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile
Glu Xaa Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro
Pro Ser 35 431PRTArtificial SequenceFormula (E); Description of
Artificial Sequence Synthetic polypeptide 4Xaa Xaa Xaa Xaa Thr Phe
Thr Ser Asp Val Ser Ser Tyr Xaa Glu Gly 1 5 10 15 Gln Ala Ala Lys
Glu Phe Ile Ala Xaa Leu Val Xaa Gly Arg Xaa 20 25 30
534PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 5Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu
Glu Glu Glu Ala Val 1 5 10 15 Arg Leu Phe Ile Glu Trp Leu Lys Gln
Gly Gly Pro Ser Lys Glu Ile 20 25 30 Ile Ser 625PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 6Gly
Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val 1 5 10
15 Arg Leu Phe Ile Glu Phe Leu Lys Asn 20 25 727PRTArtificial
SequenceR4; Description of Artificial Sequence Synthetic
polypeptide; see specification as filed for detailed description of
substitutions and preferred embodiments 7Xaa Xaa Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu 1 5 10 15 Ala Val Arg Leu
Phe Ile Glu Phe Leu Lys Asn 20 25 838PRTArtificial SequenceR4;
Description of Artificial Sequence Synthetic polypeptide; see
specification as filed for detailed description of substitutions
and preferred embodiments 8Xaa Xaa Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Leu Glu Glu Glu 1 5 10 15 Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser Ser 20 25 30 Gly Ala Pro Pro Pro Ser 35
936PRTArtificial SequenceR4; Description of Artificial Sequence
Synthetic polypeptide; see specification as filed for detailed
description of substitutions and preferred embodiments 9Xaa Xaa Gly
Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu 1 5 10 15 Ala
Val Arg Leu Phe Ile Glu Trp Leu Lys Gln Gly Gly Pro Ser Lys 20 25
30 Glu Ile Ile Ser 35 1038PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 10Gly Glu Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu 1 5 10 15 Ala Val Arg Leu
Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser 20 25 30 Gly Ala
Pro Pro Pro Ser 35 1136PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 11Gly Thr Phe Thr Ser Asp
Leu Ser Lys Gln Leu Glu Glu Glu Ala Val 1 5 10 15 Arg Leu Phe Ile
Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala 20 25 30 Pro Pro
Pro Ser 35 1237PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 12Pro Gly Thr Phe Thr Ser Asp Leu
Ser Lys Gln Leu Glu Glu Glu Ala 1 5 10 15 Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly 20 25 30 Ala Pro Pro Pro
Ser 35 1332PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 13Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu
Glu Ala Val Arg Leu 1 5 10 15 Phe Ile Glu Trp Leu Lys Gln Gly Gly
Pro Ser Lys Glu Ile Ile Ser 20 25 30 1434PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
14Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu Glu Ala Val Arg Leu 1
5 10 15 Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser Ser Gly Ala Pro
Pro 20 25 30 Pro Ser 1526PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 15Phe Thr Ser Asp Val Ser Ser
Tyr Leu Glu Gly Gln Ala Ala Lys Glu 1 5 10 15 Phe Ile Ala Trp Leu
Val Lys Gly Arg Gly 20 25 1639PRTHeloderma horridum 16His Ser Asp
Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15 Glu
Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25
30 Ser Gly Ala Pro Pro Pro Ser 35 174PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 17Gly
Glu Gly Thr 1 1824PRTArtificial SequenceZ; Description of
Artificial Sequence Synthetic peptide; see specification as filed
for detailed description and preferred embodiments 18Thr Phe Thr
Ser Asp Leu Ser Lys Gln Xaa Glu Glu Glu Ala Val Arg 1 5 10 15 Leu
Phe Ile Glu Xaa Leu Lys Asn 20 1935PRTArtificial SequenceZ;
Description of Artificial Sequence Synthetic peptide; see
specification as filed for detailed description and preferred
embodiments 19Thr Phe Thr Ser Asp Leu Ser Lys Gln Xaa Glu Glu Glu
Ala Val Arg 1 5 10 15 Leu Phe Ile Glu Xaa Leu Lys Asn Gly Gly Pro
Ser Ser Gly Ala Pro 20 25 30 Pro Pro Ser 35 2024PRTArtificial
SequenceZ; Description of Artificial Sequence Synthetic peptide;
see specification as filed for detailed description and preferred
embodiments 20Thr Phe Thr Ser Asp Leu Ser Lys Gln Xaa Glu Glu Glu
Ala Val Arg 1 5 10 15 Leu Phe Ile Glu Xaa Leu Lys Xaa 20
2127PRTArtificial SequenceZ; Description of Artificial Sequence
Synthetic peptide; see specification as filed for detailed
description and preferred embodiments 21Thr Phe Thr Ser Asp Val Ser
Ser Tyr Xaa Glu Gly Gln Ala Ala Lys 1 5 10 15 Glu Phe Ile Ala Xaa
Leu Val Xaa Gly Arg Xaa 20 25 2210PRTArtificial SequenceDescription
of Artificial Sequence Synthetic peptide 22Gln Gly Gly Pro Ser Lys
Glu Ile Ile Ser 1 5 10 2312PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 23Gln Gly Gly Pro Ser Ser Gly
Ala Pro Pro Pro Ser 1 5 10 244PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 24Asn Gly Gly Pro 1
255PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 25Asn Gly Gly Pro Ser 1 5 266PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 26Asn
Gly Gly Pro Ser Ser 1 5 277PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 27Asn Gly Gly Pro Ser Ser Gly
1 5 288PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 28Asn Gly Gly Pro Ser Ser Gly Ala 1 5
299PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 29Asn Gly Gly Pro Ser Ser Gly Ala Pro 1 5
3010PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 30Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro 1 5 10
3111PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 31Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Pro 1 5
10 3211PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 32Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Ser 1 5
10 3312PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 33Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Ser Lys
1 5 10 3417PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 34Asn Gly Gly Pro Ser Ser Gly Ala Pro Pro Ser Lys
Lys Lys Lys Lys 1 5 10 15 Lys 3513PRTArtificial SequenceDescription
of Artificial Sequence Synthetic peptide 35Asn Gly Gly Pro Ser Ser
Gly Ala Pro Pro Pro Ser Lys 1 5 10 364PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 36His
Gly Glu Gly 1 374PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 37His Ala Glu Gly 1 3839PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 38His
Ala Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10
15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
20 25 30 Ser Gly Ala Pro Pro Pro Ser 35 3938PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
39Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu Glu 1
5 10 15 Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser
Ser 20 25 30 Gly Ala Pro Pro Pro Ser 35 4039PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
40His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1
5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro
Ser 20 25 30 Ser Gly Ala Pro Pro Pro Ser 35 4139PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
41His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1
5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro
Ser 20 25 30 Ser Gly Ala Pro Pro Pro Ser 35 4239PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
42His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1
5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro
Ser 20 25 30 Ser Gly Ala Pro Pro Pro Ser 35 4328PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 43His
Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10
15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn 20 25
4428PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 44His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys
Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu
Lys Asn 20 25 4528PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 45His Gly Pro Gly Thr Phe Thr Ser Asp
Leu Ser Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile
Glu Phe Leu Lys Asn 20 25 4636PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 46His Gly Pro Gly Thr Phe
Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly
Ala Pro 35 4736PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 47His Gly Pro Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro 35
4836PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 48His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Phe
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro 35
4937PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 49His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Gln Gly Gly Pro Ser 20 25 30 Lys Glu Ile Ile Ser 35
5039PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 50His Ser Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro Pro Ser 35
5129PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 51His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys
Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu
Lys Asn Gly 20 25 5229PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 52His Gly Pro Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu
Phe Ile Glu Phe Leu Lys Asn Gly 20 25 5330PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
53His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1
5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly 20
25 30 5430PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 54His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Phe
Leu Lys Asn Gly Gly 20 25 30 5531PRTArtificial SequenceDescription
of Artificial Sequence Synthetic polypeptide 55His Gly Pro Gly Thr
Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val
Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro 20 25 30
5631PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 56His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Phe
Leu Lys Asn Gly Gly Pro 20 25 30 5732PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
57His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1
5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro
Ser 20 25 30 5832PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 58His Gly Pro Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe
Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25 30 5933PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
59His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1
5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro
Ser 20 25 30 Ser
6033PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 60His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Phe
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser 6134PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
61His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1
5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro
Ser 20 25 30 Ser Gly 6234PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 62His Gly Pro Gly Thr Phe
Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg
Leu Phe Ile Glu Phe Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly
6335PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 63His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala 35
6435PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 64His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Phe
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala 35
6537PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 65His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro 35
6637PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 66His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Phe
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro 35
6738PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 67His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro Pro 35
6838PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 68His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Phe
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro Pro 35
6939PRTArtificial SequenceCompound 24B; Description of Artificial
Sequence Synthetic polypeptide 69Xaa Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro
Pro Ser Lys 35 7029PRTArtificial SequenceCompound 24C; Description
of Artificial Sequence Synthetic peptide 70Xaa Gly Glu Gly Thr Phe
Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg
Leu Phe Ile Glu Trp Leu Lys Asn Lys 20 25 7129PRTArtificial
SequenceCompound 24D; Description of Artificial Sequence Synthetic
peptide 71Xaa Ala Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met
Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn
Lys 20 25 7239PRTArtificial SequenceCompound 10J; Description of
Artificial Sequence Synthetic polypeptide 72Xaa Gly Pro Gly Thr Phe
Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly
Ala Pro Pro Pro Ser 35 7339PRTArtificial SequenceCompound 10L;
Description of Artificial Sequence Synthetic polypeptide 73Xaa Xaa
Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15
Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20
25 30 Ser Gly Ala Pro Pro Pro Ser 35 7437PRTArtificial
SequenceCompound 10M; Description of Artificial Sequence Synthetic
polypeptide 74Xaa Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln
Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys
Gln Gly Gly Pro Ser 20 25 30 Lys Glu Ile Ile Ser 35
7529PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 75His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys
Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu
Lys Asn Gly 20 25 7630PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 76His Gly Pro Gly Thr Phe
Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly 20 25 30 7731PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
77His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1
5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro
20 25 30 7832PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 78His Gly Pro Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30 7933PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
79His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1
5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro
Ser 20 25 30 Ser 8034PRTArtificial SequenceDescription of
Artificial Sequence Synthetic polypeptide 80His Gly Pro Gly Thr Phe
Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly
8135PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 81His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala 35
8237PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 82His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro 35
8338PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 83His Gly Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro Pro 35
8431PRTHomo sapiens 84His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser
Ser Tyr Leu Glu Gly 1 5 10 15 Gln Ala Ala Lys Glu Phe Ile Ala Trp
Leu Val Lys Gly Arg Gly 20 25 30 8530PRTArtificial
SequenceDescription of Artificial Sequence Synthetic polypeptide
85His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 1
5 10 15 Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg 20
25 30 8639PRTHeloderma suspectum 86His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro
Pro Pro Ser 35 8737PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 87His Gly Glu Gly Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Gln Gly Gly Pro Ser 20 25 30 Lys Glu Ile Ile
Ser 35 8839PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 88His Ala Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro Pro Ser 35
8939PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 89His Gly Pro Ala Thr Phe Thr Ser Asp Leu Ser
Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro Pro Ser 35
9039PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 90His Ala Pro Ala Thr Phe Thr Ser Asp Leu Ser
Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro Pro Ser 35
9139PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 91His Val Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro Pro Ser 35
9241PRTArtificial SequenceDescription of Artificial Sequence
Synthetic polypeptide 92His Ala Leu Ala Pro Gly Thr Phe Thr Ser Asp
Leu Ser Lys Gln Met 1 5 10 15 Glu Glu Glu Ala Val Arg Leu Phe Ile
Glu Trp Leu Lys Asn Gly Gly 20 25 30 Pro Ser Ser Gly Ala Pro Pro
Pro Ser 35 40 9328PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 93His Gly Glu Gly Thr Phe Thr Ser Asp
Leu Ser Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile
Glu Phe Leu Lys Asn 20 25 9426PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 94Pro Gly Thr Phe Thr Ser Asp
Leu Ser Lys Gln Leu Glu Glu Glu Ala 1 5 10 15 Val Arg Leu Phe Ile
Glu Phe Leu Lys Asn 20 25 9528PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 95His Val Pro Gly Thr Phe Thr
Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu
Phe Ile Glu Phe Leu Lys Asn 20 25 9628PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 96His
Ala Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10
15 Glu Ala Val Arg Leu Phe Ile Glu Phe Leu Lys Asn 20 25
9728PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 97His Cys Pro Cys Thr Phe Thr Ser Asp Leu Ser Lys
Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Phe Leu
Lys Asn 20 25 9837PRTArtificial SequenceDescription of Artificial
Sequence Synthetic polypeptide 98His Cys Pro Cys Thr Phe Thr Ser
Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe
Ile Glu Trp Leu Lys Gln Gly Gly Pro Ser 20 25 30 Lys Glu Ile Ile
Ser 35 9928PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 99His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys
Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu
Lys Asn 20 25 10024PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 100Thr Phe Thr Ser Asp Leu Ser Lys Gln
Leu Glu Glu Glu Ala Val Arg 1 5 10 15 Leu Phe Ile Glu Phe Leu Lys
Asn 20 10127PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 101Gly Glu Gly Thr Phe Thr Ser Asp Leu
Ser Lys Gln Leu Glu Glu Glu 1 5 10 15 Ala Val Arg Leu Phe Ile Glu
Trp Leu Lys Asn 20 25 10225PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 102Gly Thr Phe Thr Ser Asp
Leu Ser Lys Gln Leu Glu Glu Glu Ala Val 1 5 10 15 Arg Leu Phe Ile
Glu Trp Leu Lys Asn 20 25 1038PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 103Pro Gly Thr Phe Thr Ser
Asp Leu 1 5 10422PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 104Thr Ser Asp Leu Ser Lys Gln Leu Glu
Glu Glu Ala Val Arg Leu Phe 1 5 10 15 Ile Glu Phe Leu Lys Asn 20
10539PRTArtificial SequenceCompound 23A 105Xaa Xaa Pro Gly Thr Phe
Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly
Ala Pro Pro Pro Ser 35 10639PRTArtificial SequenceCompound 23B
106Xaa Xaa Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser 20 25 30 Ser Gly Ala Pro Pro Pro Ser 35 10739PRTArtificial
SequenceCompound 23C 107Xaa Xaa Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro Pro Ser 35
10839PRTArtificial SequenceCompound 23D 108Xaa Xaa Pro Gly Thr Phe
Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly
Ala Pro Pro Pro Ser 35 10939PRTArtificial SequenceCompound 23E
109Xaa Xaa Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser 20 25 30 Ser Gly Ala Pro Pro Pro Ser 35 11039PRTArtificial
SequenceCompound 23F 110Xaa Xaa Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro Pro Ser 35
11139PRTArtificial SequenceCompound 23G 111Xaa Xaa Pro Gly Thr Phe
Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5
10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro
Ser 20 25 30 Ser Gly Ala Pro Pro Pro Ser 35 11239PRTArtificial
SequenceCompound 23G 112Xaa Xaa Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro Pro Ser 35
11339PRTArtificial SequenceCompound 23I 113Xaa Xaa Pro Gly Thr Phe
Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly
Ala Pro Pro Pro Ser 35 11439PRTArtificial SequenceCompound 23J
114Xaa Xaa Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser 20 25 30 Ser Gly Ala Pro Pro Pro Ser 35 11539PRTArtificial
SequenceCompound 23K 115Xaa Xaa Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro Pro Ser 35
11639PRTArtificial SequenceCompound 23L 116Xaa Xaa Pro Gly Thr Phe
Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg
Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly
Ala Pro Pro Pro Ser 35 11739PRTArtificial SequenceCompound 24A
117His Xaa Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu
1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly
Pro Ser 20 25 30 Ser Gly Ala Pro Pro Ser Lys 35 11839PRTArtificial
SequenceCompound 24E 118His Xaa Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Asn Gly Gly Pro Ser 20 25 30 Ser Gly Ala Pro Pro Ser Lys 35
11927PRTArtificial SequenceCompound 24F 119His Xaa Pro Gly Thr Phe
Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 1 5 10 15 Glu Ala Val Arg
Leu Phe Ile Glu Trp Leu Glu 20 25 12013PRTArtificial
SequenceCompound 24G 120His Xaa Pro Gly Thr Phe Thr Ser Asp Leu Ser
Glu Lys 1 5 10 12139PRTArtificial SequenceCompound 10K 121Xaa Xaa
Pro Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Leu Glu Glu 1 5 10 15
Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 20
25 30 Ser Gly Ala Pro Pro Pro Ser 35 12237PRTArtificial
SequenceCompound 10N 122Xaa Xaa Pro Gly Thr Phe Thr Ser Asp Leu Ser
Lys Gln Leu Glu Glu 1 5 10 15 Glu Ala Val Arg Leu Phe Ile Glu Trp
Leu Lys Gln Gly Gly Pro Ser 20 25 30 Lys Glu Ile Ile Ser 35
* * * * *